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Chapter 1 - Abstract 
 
Chlamydia trachomatis (Chlamydia) is the most common sexually transmitted 
infection diagnosed in genitourinary medicine (GUM) clinics and affects one in ten 
sexually active young people. Neisseria gonorrhoeae (gonorrhoea) is the second most 
common.  They are asymptomatic in at least three-quarters of patients. Untreated 
infection can lead to serious health problems; including pelvic inflammatory disease 
and infertility in women.  In men, it can cause urethritis and Reiter‟s Syndrome 
(arthritis).  The number of diagnoses of uncomplicated chlamydia in GUM clinics in 
England increased by 288% between 1995 and 2006
1
. 
 
Co infection with chlamydia and gonorrhoea is not uncommon. Up to half of patients 
diagnosed may be infected with both pathogens and, therefore, it is important to test 
sexually active individuals for both chlamydia and gonorrhoea using a multiplex 
system
2
. 
 
Electrochemical detection of specific DNA sequences offers advantages over 
established fluorescence techniques; including cost and ease of miniaturisation.  The 
electrochemical gene sensor described here uniquely utilises enzymatic T7 
Exonuclease digestion to generate ferrocenylated oligonucleotide fragments in a 
matched (gene sequence presence) sensor.  These fragments exhibit a 
characteristically high response upon electrochemical analysis, using Differential 
Pulse Voltammetry and have been designed based on the ability to „tune‟ the 
oxidation potential of ferrocene by using electron-withdrawing and electron-donating 
substituent groups.  Ferrocenylated oligonucleotide labels have been synthesised, each 
with a characteristic oxidation potential. 
 
Results from a study of the adsorption and electron transfer kinetics of T7 
exonuclease - digested and undigested oligonucleotide redox probes at screen-printed 
carbon paste electrode (SCPE) surfaces will be considered as a basis for the assay 
discrimination.  The high selectivity of the T7 Exonuclease digest is demonstrated 
using the ferrocenylated oligonucleotides and a triplex genomic electrochemical assay 
for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and the human 
 7 
beta-actin gene as an internal control for the assay using clinical samples will be 
presented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
Chapter 2 - Introduction 
 
2.1 The Biosensor 
 
A Biosensor is defined as an analytical device incorporating a biological material, a 
biologically derived material or a biomimetic intimately associated with or integrated 
within a physicochemical transducer or transducing microsystem, which may be 
optical, electrochemical, thermometric, piezoelectric, magnetic or micromechanical
3
. 
 
Biosensors usually yield a digital electronic signal which is proportional to the 
concentration of a specific analyte or group of analytes and as such, biosensors have 
been applied to a wide variety of analytical problems including in medicine, drug 
discovery, the environment, food, process industries, security and defense
3
. 
 
Clinical Diagnostic biosensors are established entities within the healthcare sector as 
they are integral to the detection and management of disease.  Until c.1980, bacterial 
culture was the only method for establishing diagnoses of certain infections and the 
technique is still in use in medico-legal cases today due to its high-specificity
4
.  
Bacterial culture, however, remains time-consuming and highly-specialised.  In 1986, 
Enzyme immunoassay (EIA) was introduced as a detection method for Chlamydia
5
.  
The method proved less expensive and more user-friendly; however it did present 
specificity issues
5
.  The objective of a large quantity of current research in the fields 
of virology, bacteriology and biosensor systems is to evaluate the clinical applicability 
of multiplex polymerase chain reaction (PCR), as detailed further in section 3.5.2.  
Brittain-Long et al. for example, have recently developed a real-time PCR procedure 
for the detection of respiratory tract infections, based on automated specimen 
extraction and multiplex amplification, at a relatively low cost (€33)6.  This particular 
research also confirmed that it is often very difficult for the clinician to distinguish 
between viral and bacterial aetiologies, and this may result in the overuse of 
antibiotics
7
.  Furthermore, the study detailed that diagnosis of viral respiratory tract 
infections using viral culture, antigen detection or serology is either too slow or too 
insensitive to be applicable in clinical practice
8
.  Nucleic acid amplification-based 
methods are now of prime importance for the diagnosis of bacterial infections
9
.  A 
 9 
number of commercial products using nucleic acid amplification technology are now 
available
10
.  These tests amplify the target nucleic acid, DNA or ribonucleic acid 
(RNA); or the probe after it has annealed to target nucleic acid.  Such tests are 
generally more sensitive than liquid or solid phase hybridisation tests which do not 
embody an amplification process
10
 and are considerably more sensitive than culture or 
antigen detection methods
11
. 
 
 
2.2 Sexually Transmitted Infections – Chlamydia trachomatis (CT) and Neisseria 
gonorrhoeae (NG) 
 
2.2.1 Chlamydia trachomatis 
 
According to the United Kingdom (UK) Health Protection Agency (HPA), Genital 
chlamydial infection remained the most commonly diagnosed bacterial sexually 
tramsmitted infection (STI) in UK genitourinary medicine (GUM) clinics in 2006, 
comprising 30% (113585 / 376508) of all new STI diagnoses in this setting.  If 
untreated, Genital chlamydia can lead to pelvic inflammatory disease, ectopic 
pregnancy and tubal infertility in women and can affect sperm function and fertility in 
men.  At least 70% of women and 50% of men with chlamydial infection show no 
symptoms and may remain undiagnosed in the absence of screening for asymptomatic 
infection
12
.  The annual cost of chlamydia and its consequences in the UK is 
estimated to be more than £100 million
13
.   
 
Countries within the UK vary in their approaches to prevention and control of 
chlamydia.  In Scotland there is no specific centrally led programme but clear 
guidance is given to health professionals in the form of the evidence-based Scottish 
Intercollegiate Guidelines Network
14
.  These will be updated in 2008 but currently 
recommend the testing of all patients attending GUM clinics, all women undergoing 
termination of pregnancy, all symptomatic men and women in any clinical setting, 
and opportunistic screening of all sexually active women aged under 25 and women 
aged over 25 with two or more partners or a change of partners in the previous year
15
. 
 
 10 
Since 2003, there has been a proactive policy in England, the National Chlamydia 
Screening Programme (NCSP), which is a key part of the government‟s strategy for 
the modernisation of sexual health services.  Its introduction has occurred in three 
phases to enable managed growth.  Full roll out to the 152 Primary care Trusts (PCTs) 
in England will be almost completed by the end of 2007.  The NCSP targets all 
sexually active men and women under 25 with multifaceted opportunistic screening 
involving a diverse range of settings in both healthcare and non-healthcare locations.  
Effective partner notification to reduce the risk of re-infection and reinforce health 
education messages is integral to the programme
15
. 
 
2.2.2 Neisseria gonorrhoeae 
 
Gonorrhoea is the second most common bacterial sexually transmitted infection in the 
UK which, if untreated, can lead to complications such as chronic pelvic pain, ectopic 
pregnancy and infertility in women.  In 2006, there were 19007 diagnoses of 
uncomplicated gonorrhoea in GUM clinics in the UK, 13627 in men and 5380 in 
women.  This translates to an overall rate of 46 and 18 per 100000 population in men 
and women respectively
16
.  Numbers and rates of gonorrhoea diagnoses are highest in 
men partly because men are more likely to be symptomatic, but also because a 
significant proportion of cases are acquired through sex between men
17
. 
 
Targeted interventions are particularly appropriate for gonorrhoea as it is concentrated 
in specific population sub-groups
18
.  As the great majority of gonorrhoea diagnoses 
are still made in GUM clinics, reinforcing and enhancing primary and secondary 
prevention activities within this setting could have a significant impact on infection 
control.  Indeed, recent improvements in patient waiting times
19
, the increase in 
numbers of sexual health screens being done, and evidence of improved partner 
notification within the GUM clinic setting may all have helped interrupt heterosexual 
transmission of gonorrhoea in recent years
20, 21
. 
 
Outside of the GUM clinic setting, there is increasing evidence that in certain 
localised areas where chlamydia screening is being introduced, some sites are also 
testing specimens for gonorrhoea
22, 23, 24
.  The evidence base for wider use of 
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gonococcus nucleic acid amplification tests is growing and it is proposed that their 
use should be the subject of formally designed studies so as to better inform the 
development of national policy
25
. 
 
 
2.3 Emerging Clinical Requirements for Point of Care Diagnostic Testing for CT 
and NG. 
 
Clinical Biochemistry produces and interprets the results of chemical and biochemical 
analyses performed on blood and other body fluids to help in the diagnosis and 
management if disease
26
.  Consequently, sensors for bacterial pathogens have 
advanced rapidly within this sector of public healthcare. A survey of General 
Practitioners in England and Wales by the Public Health Laboratory Service indicated 
that, among infectious diseases, the greatest opportunity for improving public health 
was seen to be the better management of chlamydial genital tract
27
.  Improved 
availability of diagnostic tests for chlamydial infections was also a major priority
28
 
 
Co-infection with CT and NG is not uncommon. In fact, up to half of patients 
diagnosed may be infected with both pathogens and, therefore, it is important to test 
all sexually active individuals for both CT and NG29. 
 
Figure 1 illustrates the current rates of increase in newly diagnosed cases of CT and 
NG. 
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Figure 1: The Number of New Episodes of Diagnoses of Chlamydia and Gonorrhoea in the UK, 2002-
2006.  Source: UK Health Protection Agency Annual 2006 STI Data. 
 
The high prevalence of asymptomatic gonoccocal and chlamydial infections is one of 
the greatest obstacles to STI control, especially in developing countries, where partner 
notification is difficult.  A widely available diagnostic test which allowed prompt and 
effective treatment of asymptomatic patients could reduce the prevalence of these 
infections, prevent complications, and reduce the incidence of HIV infection, whose 
transmission they facilitate.  Such a test could also play an important part in reducing 
unnecessary treatment of patients with STI syndromes that are not caused by these 
pathogens
30
. 
 
Most current tests for Neisseria gonorrhoeae and Chlamydia trachomatis require the 
support of a laboratory, and results are not usually available before the patient has left 
the clinic.  This delay can lead to patients not returning for treatment and may allow 
further STI transmission to occur.  Current rapid point of care (POC) STI tests and the 
syndromic approach are less sensitive than gold standard tests, but allow treatment at 
the initial visit. 
 
Vickerman et al
31 
developed a mathematical model to compare the STIs averted using 
different STI diagnostic metods.  The results of this study indicated that the required 
sensitivity of a POC test is low if there is significant STI transmission during the 
delay in treatment for the gold standard test and/or few patients return for treatment.  
 13 
For example, the required sensitivity of a POC test for C. trachomatis is 50% (gold 
standard sensitivity is 90%) if either 55% return for treatment and there is no STI 
transmission, or 80% return for treatment and 50% of infected patients infect their 
partner during the delay in treatment.  Furthermore, in these settings a POC test of 
moderate sensitivity can lead to significantly more STI averted than the gold standard 
test. 
 
These results support the use of moderate sensitivity POC tests in scenarios where 
many patients will not return for treatment, and in populations where the delay in 
treatment would result in significant STI transmission
32
.     
 
 
2.4 Established Methodology for STI Diagnosis 
 
2.4.1 Cell Culture Assays 
 
Until the early 1980s, the main method of confirming a diagnosis of chlamydial 
infection was the inoculation of clinical material into animals, or more commonly, 
tissue culture cells and the demonstration of characteristic chlamydial inclusions.  
Usually, inclusions were demonstrated in cell culture, either by staining with iodine, 
Giemsa stain, fluorochrome-labelled poly- or mono-clonal antibody or by enzyme 
immunohistochemistry.  The procedures involved in diagnosis by cell culture meant 
that chlamydial diagnoses were performed by a few specialist research laboratories.  
The main advantage was that identification of even one chlamydial inclusion was 
usually sufficient to establish a definitive diagnosis.  Even now cell culture is one 
reference standard against which new diagnostic tests can be compared and it is still 
the method of choice for medico-legal cases, for example child sexual abuse.  Tissue 
culture services are however labour intensive and expensive to maintain with many 
variables including the tissue culture water, the particular clone of cells in use and the 
elimination of adventitious mycoplasma infection
33
. 
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2.4.2 Immunoassays 
 
Demanding, but less variable protocols associated with modern, non viability-
dependent diagnostic products with better sensitivity than was routinely achieved 
through cell culture techniques have since been developed
33
.  The first commercial 
enzyme immunoassay (EIA) for the detection of chlamydial antigen in clinical 
specimens was the Abbott Chlamydiazyme
®34
.  The Chlamydiazyme was based on an 
adsorbed polyclonal antiserum, rather than a monoclonal antibody.  It soon became 
clear that there were specificity problems, however, associated with the finding that 
the enzyme immunoassay antibody reacted with strains of Acinetobacter 
calcoaceticus, Escherichia coli, Gardnerella vaginalis, Neisseria gonnorrhoeae and 
group B streptococci
35
.  In women, urinary tract infection could cause false positive 
results
36
.  However, specificity was improved by the introduction of a confirmation 
test blocking antibody
37
. 
 
The Boots-Celltech (subsequently DAKO) IDEIA
®
 was introduced to the market as a 
radically different immunoassay, being based on the improved specificity of 
monoclonal antibody to the chlamydia-specific lipopolysaccharide epitope plus a 
novel redox-linked, signal amplification system
38
.  Early results suggested that the 
sensitivity and specificity of these assays for use on endocervical or endourethral 
specimens were broadly comparable
39
. 
 
A range of rapid, qualitative enzyme immunoassay-based diagnostic tests for 
chlamydial antigen were also developed, aimed at point of care diagnosis; including 
the Unipath Clearview
®
, the Kodak Surecell
®
 and the Quidel Quickview
®
.  The 
general impression is that these qualitative tests had lower sensitivity than their less 
rapid but quantitative counterparts.  Rani et al
40
 conducted a pilot study to evaluate 
the sensitivity and specificity of the Quidel Quickview
®
 Chlamydia test in populations 
with a low and high prevalence of chlamydial genital tract infection.  Furthermore, 
these results were compared to PCR for endocervical samples.  The sensitivity and 
specificity of the QuickVue test compared to PCR was 65% and 100% respectively 
for the high prevalence population and 25% and 100% respectively for the low 
prevalence population.  The sensitivity of the QuickVue test for a high prevalence 
population was comparable to laboratory-based enzyme immunoassay techniques, but 
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not to nucleic acid amplification based methods.  However, for a low prevalence 
population, this test, due to low sensitivity, failed to identify one in four cases.  
 
Many laboratories still use chlamydial antigen detection immunoassays because of 
their ease of use and lower cost.  However, research interest in this methodology 
waned with the introduction of superior methods based on nucleic acid hybridisation 
and amplification.  
 
2.5 DNA Methods 
 
2.5.1 Deoxyribonucleic acid (DNA) 
 
Deoxyribonucleic acid (DNA) is a nucleic acid that contains the genetic instructions 
specifying the biological development of all cellular forms of life and many viruses.  
DNA is a polymer with monomer units called nucleotides. Hence, the polymer is 
known as a "polynucleotide." Each nucleotide consists of a 5-carbon sugar 
(deoxyribose), a nitrogen-containing base attached to the sugar, and a phosphate 
group. There are four different types of nucleotides found in DNA, differing only in 
the nitrogenous base, given one letter abbreviations as shorthand for the four bases.  
Adenine (A), Guanine (G), Cytosine (C) and Thymine (T).  Adenine and guanine are 
substituted purines and cytosine and thymine are substituted pyrimidines.  In 1953, 
James Watson and Francis Crick proposed the now classic secondary structure of 
DNA
41
.  According to the Watson - Crick Model, DNA consists of two 
polynucleotide strands coiled around each other in an anti-parallel direction to form a 
double helix (Figure 2).  The strands are connected by bases, hydrogen bonded 
together in a highly specific way.  A and T form strong hydrogen bonds to each other 
but not to C or G, while C and G form strong hydrogen bonds to each other but not to 
A or T (Figure 3). 
 16 
 
Figure 2: The Double Helix Model of DNA.  Image courtesy of U.S. National Library of Medicine. 
 
Figure 3: Base Pairing in DNA.  Image courtesy of www.cse.ucsc.edu. 
 
The four nucleotide constituents of DNA have in common a 5‟ phosphoryl and 3‟ 
hydroxyl group by reference to their positions in the deoxyribose sugar molecule.  
The formation of phosphate bonds between the 5‟ and 3‟ positions of the constituent 
nucleotides results in the DNA molecule, as exemplified in Figure 4. 
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Figure 4: Phosphate bonding forming a polynucleotide. 
 
2.5.2 The Polymerase Chain Reaction (PCR) 
 
The polymerase chain reaction (PCR) first appeared in 1985 as a method for the 
prenatal diagnosis of sickle cell anaemia
42
.  It was based on the remarkable insight of 
Kary Mullis, who realised that repetition of a DNA extension reaction bounded by 
two synthetic nucleotide primers would generate a large quantity of any specified 
DNA sequence
43
.  
 
Biosensory investigation of DNA requires that enough of the DNA under study is 
available for analysis.  PCR exploits the natural function of polymerase enzymes 
which copy genetic material and proofread and correct the copies.  PCR requires a 
template molecule- the DNA and two primer molecules to start the copying process.  
The primers are short chains of the four bases and they must be duplicates of 
nucleotide sequences on either side of the piece of DNA of interest.  There are three 
basic processes involved in PCR, as exemplified in Figure 5. 
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Figure 5: Polymerase Chain Reaction.  Image courtesy of http://members.aol.com 
 
Firstly, the double helix of the DNA must be denatured and separated by heating to 
90-96
o
C; a process called “melting”.  The second step is hybridisation or annealing, in 
which the primers bind to their complementary bases on the now single-stranded 
DNA.  The annealing temperature (or melt temperature) is described as the 
temperature at which two strands of polynucleotides will chemically bind to form a 
duplex.  As expected, annealing temperatures are specific to particular DNA 
sequences.  The third is DNA synthesis by a polymerase.  Starting from the primer, 
the polymerase can read a template strand and match it with complementary 
nucleotides.  The result is two new helixes in place of the first, each composed of one 
of the original strands plus the newly assembled complementary strand.  The amount 
of double stranded DNA produced increases exponentially and using commercially 
available equipment, millions of copies of a specific DNA strand can be obtained.  
The PCR process whereby each strand of the duplex is amplified as many times as its 
counterpart is referred to as “symmetric PCR” i.e., the same concentration of forward 
and reverse primer is utilised. 
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2.5.3 Human and Pathogenic Genome Characterisation 
 
Completed in 2003, the Human Genome Project (HGP) was a 13-year project 
coordinated by the U.S. Department of Energy and the National Institutes of Health.  
The primary project goals were to identify all the approximately 20000-25000 genes 
in human DNA and to determine the sequences of the 3 billion chemical base pairs 
that make up human DNA
44
. 
 
Alongside the HGP, parallel projects have run in order to characterise pathogen 
genomics.  In 1995, the first microbe sequencing project, Haemophilus influenzae was 
completed.  Encouraged by the success of that initial effort, researchers have 
continued to sequence an impressive array of other medically important microbes.  
The National Institute of Allergy and Infectious Disease (NIAID) has made 
significant investments in large-scale sequencing projects and includes projects to 
sequence the complete genomes of many pathogens, including C. trachomatis as well 
as the bacteria that cause tuberculosis, gonorrhoea and cholera and organisms that are 
considered agents of bioterrorism
45
.   
 
2.5.4 DNA-based Assays 
 
Nucleic acid amplification-based methods are now of prime importance for the 
diagnosis of chlamydial infections
46
.  A number of commercial products using nucleic 
acid amplification technology are currently available
47
.  These tests amplify the target 
nucleic acid, DNA or ribonucleic acid (RNA); or the probe after it has annealed to 
target nucleic acid.  Such tests are generally more sensitive than liquid or solid phase 
hybridisation tests, which do not embody an amplification process
48
 and are 
considerably more sensitive than culture or antigen detection methods
49
. 
 
The major targets for amplification-based tests against C. trachomatis are generally 
multiple-copy gene products, such as the cryptic chlamydial plasmid or ribosomal 
RNA.  Starting from a multiple copy gene offers a clear starting advantage with 
respect to sensitivity.  Initial nucleic acid amplification based tests were based on the 
detection of chlamydial DNA in clinical samples.  The well documented PCR, e.g. the 
Roche Amplicor
®
 PCR, uses selected primers, nucleotide triphosphates (NTPs) and 
 20 
taq polymerase to amplify chlamydial DNA sequences, which are captured by 
hybridisation on oligonucleotide-coated microplates.  The Roche Amplicor
®
 PCR was 
the first commercial nucleic acid amplification test to be made available for the 
diagnosis of human chlamydial infections. 
 
The more recent BDProbeTec
®
ET (Becton Dickinson, USA) C. trachomatis and 
Neisseria gonorrhoeae amplified DNA assay uses a novel isothermal strand 
displacement amplification (SDA) method coupled with fluorescent energy transfer 
(ET) measurement to detect amplified product as it is produced
50, 51
. 
 
In late 2006, a variant strain of C. trachomatis with a 377 base pair deletion in the 
cryptic plasmid was reported from Sweden
52
.  Prevalence was as high as 65% in some 
regions of the country.  Some commercial nucleic acid amplification tests (NAATs) 
use primers that detect this region of the cryptic plasmid and therefore cannot detect 
the variant.  The identification of a variant strain at a high prevalence has caused 
widespread concern in countries that undertake substantial volumes of testing using 
these methods.  A requirement for a novel assay able to determinine chlamydial strain 
variance is currently emerging in GUM
53
.
 
To date there is no evidence of variant 
strains in England or Wales; however the HPA is conducting a survey to determine 
whether variants are present. 
 
The main advantage of the nucleic acid amplification-based diagnosis for Chlamydia 
is that such methods combine unsurpassed sensitivity with good specificity.  
However, the greater sensitivity of these assays means that accidental contamination 
with amplified product (amplicon) is a problem of major importance for device 
design, laboratory workflow and personnel.   
 
2.5.5 Fluorescent Detection Methods 
 
The use of photolabile schemes, coupled with photochemical screeing techniques and 
combinatorial phosphoramidite chemistry, allows for the fabrication of „gene-chips‟ 
for massively parallel detection of target DNA sequences
54
.  Optical biosensors based 
on fluorescence are highly sensitive and arrays containing thousands of unique probe 
sequences have been constructed
55
.  Owing to the sophisticated and expensive nature 
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of the instrumentation required, gene-chip technology is best suited for laboratory 
applications.  Cases in which large numbers of genes or sequences need to be 
simultaneously sampled, as in transcription profiling or single nucleotide 
polymorphism (SNP) discovery, are well suited to gene chip analysis
56-59
.  Clinical 
diagnostics do not generally require such large data accumulation.  However, 
reliability and generality irrespective of sequence is required.  Besides the cost and 
sophistication of the instrumentation, the inconsistent yields of target synthesis and 
labelling, as well as non-uniform rates of fluorophore photobleaching can result in 
accuracies lower than those required for patient diagnosis
60
.   
 
Surface plasmon resonance (SPR), reports changes in the refractive index of thin 
metal film substrates that occur on adsorption of the analyte and is suitable for target 
detection in an array-based format
61
.  To achieve detection limits sufficient for a 
diagnostically useful signal, it is usually necessary to amplify the hybridisation signal 
by increasing the amount of material deposited at the metal film surface, either before 
or after target capture.  As with fluorescence-based techniques, SPR systems can be 
complex and costly, rendering them generally more suitable for research applications. 
 
Perhaps the most straightforward optical readout technology involves single-stranded 
DNA labelled with gold nanoparticles that simply change colour upon hybridisation 
of the target sequences
62
.  Using photographic silver developing solutions, a 
„scanometric‟ small array platform for DNA analysis at a flatbed scanner has been 
demonstrated using this technology with 100pM sensitivity
63
.  This technology, 
offering simplicity and sensitivity, could provide a useful approach for clinical 
diagnostic development with optical readout. 
 
2.5.6 Electrochemical DNA Sensors 
 
Electrochemical methods are well suited for DNA diagnostics.  Because 
electrochemical reactions give an electronic signal directly, there is no need for 
expensive signal transduction equipment.  Moreover, because immobilised probe 
sequences can be readily confined to a variety of electrode substrates, detection can be 
accomplished with an inexpensive electrical analyser.  Portable systems for clinical 
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testing and on-site environmental monitoring have been developed.  Sensitive 
electrochemical signalling strategies based on the direct or catalysed oxidation of 
DNA bases, as well as the redox reactions of reporter molecules or enzymes recruited 
to the electrode surface by specific DNA probe-target interactions and by charge 
transport reactions mediated by the π-stacked base pairs have all been demonstrated64.  
Since Paleček discovered the electrochemical activity of nucleic acids65 and 
sequentially, the systematic research in electrochemical DNA sensors started at the 
beginning of the 1990s, electrochemical DNA sensors were studied deeply and 
attracted considerable attention in clinical examination of inherited diseases and drug 
screening.  Most of the electrochemical DNA biosensors are based on hybridization 
using the following procedures: 1) The ssDNA probe (or target) is immobilized onto a 
solid electrode surface. 2) The ssDNA probe (or target) is bound to its complementary 
strand presenting in a sample solution forming a double helix structure on the 
electrode surface. 3) A measurable electrochemical signal caused by an electro-active 
label or redox-active intercalator or the different electrochemical behavior of ssDNA 
and double-stranded DNA (dsDNA) after hybridization.  An ideal immobilization 
method has to meet two requirements: 1) the electrode surface of the DNA biosensor 
allows effective and only specific binding of the ssDNA probe (or target) and (2) after 
the immobilization of ssDNA, the electrode surface remains electro-active for 
detecting DNA hybridization
66
.  With the development of electrochemical DNA 
biosensors, there are effective methods reported for DNA immobilizing on electrode 
surface, such as electrostatic attraction, chemical adsorption, covalent-binding, 
antigen-antibody method
66
, incorporating with a polymer matrix
66
 and molecular self-
assembly
66
 on bare or chemically modified electrodes. The earliest and simplest DNA 
immobilization strategy was just dispersing DNA molecules on an electrode substrate 
until they were physically adsorbed onto the electrode surface. This method didn‟t 
require special chemical modification of the DNA or/and the electrode surface; 
therefore, it resulted in simplicity and ease of operation. However, the adherence of 
the DNA bases to the substrate led to an inaccessibility of the immobilized DNA 
during hybridization
66
. 
 
 
 
 
 
 23 
2.5.7 Array Sensors 
 
Recently, a large number of designs for DNA-based electrochemical sensing have 
appeared.  These types of sensors combine nucleic acid layers with electrochemical 
transducers to provide a biosensor and aim to provide a simple, accurate and 
inexpensive platform for patient diagnosis.   
 
In a typical configuration, a single-stranded probe sequence is immobilised within the 
recognition layer, where base-pairing interactions recruit the target DNA to the 
surface.  The repetitive, essentially uniform structure of DNA makes its assembly on 
the recognition surface well defined.  It is at this interface that the critical dynamics of 
the target capture take place to generate the recognition signal; therefore, 
immobilising nucleic acid probe sequences in a predictable manner while maintaining 
their affinity for target DNA is crucial to overall device performance
67
. 
 
The earliest electrochemical DNA sensing strategy was based on reduction and 
oxidation of DNA at a mercury electrode.  The amount of DNA reduced or oxidised 
reflected the amount of DNA captured.  Palecek et al.
68
 developed methods to 
discriminate single- against double-stranded DNA through direct DNA reduction.  
More recently, DNA oxidation has been carried out through adsorption stripping 
voltammetry (ASV)
69
.  This technique achieves high sensitivity by inducing an 
electrostatic accumulation of analyte at the electrode surface before the detection step.  
The purine bases of DNA can be oxidised electrochemically, and this process can be 
carried out using carbon, gold, indium tin oxide (ITO) and polymer-coated 
electrodes
70
. 
 
Although this methodology is inherently sensitive, its application is complicated by 
significant background currents at the relatively high potentials required for direct 
DNA oxidation.  Numerous methods to improve the signal-to-noise ratio have been 
developed, but more recent designs employ physical separation techniques to remove 
the sources of background interference.  For example, Palecek et al.
71
 and Wang et 
al.
72
 have separately reported a two-step strategy for capturing target sequences using 
probe DNA immobilised onto magnetic beads.  After target hybridisation, the beads 
are magnetically sepatated from the pool of analytes.  The collected DNA is 
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depurinated in acidic solution, and the free guanine and adenine nucleosides are 
collected and analysed using ASV.  As few as 40 femtomoles of substrate have been 
detected using this assay. 
 
A similar technique using the direct guanine oxidation signal at carbon paste 
electrodes has recently been reported, in which specific genotypes of the factor V 
Leiden mutation in PCR amplicons were identified
73
.  The use of peptide nucleic acid 
probes
74
 affords more stringent control over hybridisation, and recent studies have 
shown that point mutations in target DNA can be more readily discerned using this 
methodology. 
 
Methods to oxidise target DNA indirectly through the use of electrochemical 
mediators have also been explored.  An interesting approach uses polypyridyl 
complexes of Ru(II) and Os(II) to mediate the electrochemical oxidation of guanine.  
Yang et al.
75
 have used this method to detect trinucleotide-repeat expansions, in 
which catalytic currents due to the oxidation of guanine residues immobilised within 
the target sequence show a linear dependence on the repeat number.  This same 
technique has been coupled to a reverse transcription-PCR assay to monitor the over-
expression of genes in tumour samples
76
.  Experiments with model PCR products 
have shown that the sensitivity of this system extends down to 550 attomoles of target 
DNA. 
 
Several strategies have been pursued in which target DNA sequences are labelled with 
redox-active reporter molecules.  Appearance of the characteristic electrochemical 
response of the redox reporter therefore signals the hybridisation event
77, 78
.  A 
variation on this approach involves a three-component „sandwich‟ assay, in which the 
redox label has been attached to a synthetic sequence specifically designed to bind to 
an overhang portion of the probe-target complex
79
.  This dual hybridisation approach 
eliminates the need to modify the target strand, with the function of bringing together 
the probe and labelled sequences.  In one example, ferrocene-labelled reporter strands 
signal the presence of target DNA hybridised to thiolated probe sequences 
immobilised onto gold electrodes.  Incorporation of a second redox reporter 
(dimethylcarbamyl ferrocene), with an oxidation potential 170mV more positive than 
the ferrocene analogue, allows the detection of two targets simultaneously and 
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without spatial separation, much like a multicolour fluorescence labelling assay
80
.  
Using AC voltammetry, the detection of 50nM target concentrations and the 
identification of a GT single-base mismatch was accomplished. 
 
Colloidal gold nanoparticles have also been employed to signal hybridisation in a 
sandwich-based assay.  In one study, the labelled target is captured by probe strands 
immobilised on a graphite electrode, and hybridisation is detected electrochemically 
with the appearance of a characteristic gold oxidation signal
81
.  The signal is greatly 
enhanced because of the large electrode surface area and the availability of many 
readily oxidised gold atoms in each nanoparticle label.  The detection limit for PCR 
amplicons was found to be as low as 0.8 femtomoles of DNA. 
 
Through the use of nanoparticle labels with different redox potentials, Wang et al.
82
 
have developed a technique in which these nanoparticles encode DNA sequences.  
Probe modified magnetic beads are hybridised with target DNA, separated 
magnetically from the pool of analytes and hybridised again with the nanoparticle-
labelled reporter strands.  The products are isolated, and the nanoparticles are 
dissolved and analysed by ASV.  Electrochemical detection of three targets 
simultaneously was demonstrated with CdS, ZnS and PbS nanoparticle tags.  
 
Many applications of DNA sensing involve extremely small numbers of target 
analytes, with correspondingly few hybridisation events.  Analyte concentration may, 
as previously considered, be increased through the use of PCR, although in addition to 
this, in an effort to improve transduction of the hybridisation signal, an electrode 
surface may also be modified with a polymer layer that confers desirable properties, 
such as electrical conductivity, amenability to probe immobilisation or protection of 
the electrode from non-specific analyte adsorption.  Heller et al.
83
 have reported an 
enzyme-amplified DNA sensing technique involving the electropolymerisation of a 
polycationic redox polymer, upon which amine-terminated oligonucleotide single 
strands are electrodeposited by ligand exchange with bipyridyl osmium complexes 
impregnated within the polymer gel. Target DNA is captured at the electrode surface 
and subsequently hybridised to a reporter strand modified with horseradish peroxidase 
(HRP).  This technique has been extended to screen-printed carbon electrodes on 
polyester sheets, which are inexpensive and amenable to mass-manufacture
84
. 
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Biocatalysed production of insoluble products has been used by Willner et al.
85
 to 
sense DNA hybridisation electrochemically at probe-modified electrodes.  Target 
DNA is captured at a probe-modified gold electrode, where a redox-active DNA 
intercalator electroanalytically generates peroxide, which, in turn, is oxidised by HRP.  
The product precipitates onto the electrode, blocking the reaction of ferricyanide and 
providing the basis for DNA detection.  In a variation on this approach, 5-bromo-4-
chloro-3-indoyl phosphate is enzymatically converted to an insoluble indigo product, 
blocking ferricyanide; using this method, the detection limit for target DNA was 
extended down to 5x10
-14
M
86
.  An enzyme-based hybridisation assay for detection of 
two DNA targets has also been described in which alkaline phosphatase and β-
galactosidase are used to differentiate between two DNA targets by measuring the 
chronopotentiometry of their electroactive products
87
.  These products yield well-
resolved oxidation signals at carbon electrodes to allow amplified dual-target 
electrochemical detection. 
 
In an alternative approach to chemical labelling schemes, redox-active reporter 
molecules that intrinsically associate with the double helix noncovalently have been 
successfully used for electrochemically based DNA analysis.  In these analyses, rather 
than serving as a reactant, the DNA is the mediator.  Such assays provide high 
sensitivity and simplicity. 
 
The notion that electrochemical reactions could be used to signal DNA hybridisation 
was first explored by Milan et al.
88
.  Their assay features a single-stranded probe 
sequence adsorbed onto glassy carbon, wherein hybridisation of target DNA caused 
and increase in the surface concentration of electrostatically bound Co(phen)3
3+
 as a 
result of the higher negative charge density at the hybridised surface.  Characteristic 
redox reactions of the cobalt probe provided the electrochemical signal.  More 
recently, Steel et al.
89
 reported the effective use of Ru(NH3)6
3+
 probe molecules to 
signal DNA hybridisation at gold films modified with thiol-bearing DNA probe 
sequences.  As the DNA is captured to form double-stranded product, proportionally 
more ruthenium hexamine binds, yielding a higher signal.   
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Work by Barton et al.
90
 has focussed on intercalative probe molecules; taking 
advantage of the electronic structure of double-helical DNA they have used, using 
intercalated redox probe molecules to report on perturbations in base stacking.  The 
DNA base pair stack mediates charge transport to the intercalary bound at the top of 
the film.  If the base pair stack is intact, the DNA mediates charge transport and 
current can flow.  This chemistry has been found to be sensitive to DNA structure and 
perturbations in structure.  Assays of DNA-mediated electrochemistry are therefore 
suited to sense changes in DNA: damage, mistakes, mismatches and even protein 
binding.   
 
2.5.8 Real Time PCR 
 
The real-time PCR system is based on the detection and quantification of a 
fluorescent reporter
91, 92
.  The signal increases in direct proportion to the amount of 
PCR product in a reaction.  By recording the amount of fluorescence emission at each 
cycle, it is possible to monitor the PCR reaction during the exponential phase where 
the first significant increase in the amount of PCR product correlates to the initial 
amount of target template.  The higher the starting copy number of nucleic acid target, 
the sooner a significant increase in fluorescence is observed
93
. 
 
A fixed fluorescence threshold is set significantly above the baseline that can be 
altered.  The parameter CT (threshold cycle) is defined as the cycle number at which 
the fluorescence emission exceeds a fixed threshold.  There are three main 
fluorescence-monitoring systems for DNA amplification
94
: hydrolysis probes, 
hybridising probes and DNA-binding agents
95, 96
.  Hydrolysis probes include TaqMan 
probes
97
, molecular beacons
98-101
 and scorpions
102- 104.  They use the fluorogenic 5‟ 
exonuclease activity of Taq polymerase to measure the amount of target sequences in 
DNA samples. 
 
TaqMan probes are oligonucleotides longer than the primers (20-30 bases long with a 
double-strand melting temperature (Tm) value of 10
o
C higher) that contain a 
fluorescent dye usually on the 5‟ base and a quenching dye (usually TAMRA) 
typically on the 3‟ base.  When irradiated, the excited fluorescent dye transfers energy 
to the nearby quenching dye molecule rather than fluorescing (this is called FRET: 
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Förster or fluorescence resonance energy transfer)
105,106
.  Thus, the close proximity of 
the reporter and quencher prevents emission of any fluorescence while the probe is 
intact.  TaqMan probes are designed to anneal to an internal region of a PCR product.  
When the polymerase replicates a template on which a TaqMan probe is bound, its 5‟ 
exonuclease activity cleaves the probe
107
.  This ends the activity of the quencher (no 
FRET) and the reporter dye starts to emit fluorescence which increases in each cycle 
proportional to the rate of probe cleavage.  Accumulation of PCR products is detected 
by monitoring the increase in fluorescence of the reporter dye.  The TaqMan assay 
uses the universal thermal cycling parameters and PCR reaction conditions.  Because 
the cleavage occurs only if the probe hybridises to the target, the origin of the detected 
fluorescence is specific amplification.  The process of hybridisation and cleavage does 
not interfere with the exponential accumulation of the product.  One specific 
requirement for fluorogenic probes is that there is no G at the 5‟end.  A G adjacent to 
the reporter dye quenches reporter fluorescence even after cleavage. 
 
All real-time PCR chemistries allow detection of multiple DNA species 
(multiplexing) by designing each probe or beacon with a spectrally unique 
fluorescence/quencher pair as long as the platform is suitable for melting curve 
analysis if SYBR green (a fluorescent DNA stain) is used.  By multiplexing, the 
targets and endogenous control can be amplified in a single tube.     
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2.6 Electrochemical Gene Sensing using T7 Exonuclease 
 
Scheme 1 outlines the processes involved during the T7 Exonuclease assay. 
 
 
 
Scheme 1: Outline of the T7 Exonuclease Assay. 
 
Target DNA is amplified using symmetric PCR with appropriate primers designed for 
the amplification of the target sequence of interest.  Upon target sequence 
amplification, T7 exonuclease and an electrochemically-active labelled DNA probe, 
specific to the amplified target sequence is introduced to the matrix and binding of the 
probe to the target sequence occurs.  T7 Exonuclease acts in the 5' to 3' direction, 
catalyzing the removal of 5' mononucleotides from duplex DNA and thus the 
electrochemically-labelled 5‟ mononucleotide is detectable at an electrode surface. 
 
If there is no target DNA present in the matrix, neither PCR nor enzymatic probe 
digestion will occur and a significantly diminished electrochemical response is 
observed. 
 
Target DNA amplification 
Probe oligonucleotide 
addition 
T7 exonuclease incubation 
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This project aims to facilitate biosensory evaluation of DNA sequences particular to C 
trachomatis and N gonorrhoeae; taking advantage of the sensitive, inexpensive and 
emerging electrochemical transduction technique.  DNA amplification techniques will 
be employed in order to improve the analyte signal and the inherent specificity of 
PCR will be exploited also. 
 
This thesis reports the development of a novel enzymatic electrochemical assay for 
the multiplex detection of C. trachomatis and N. gonorrhoeae with a validation 
internal control gene. 
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Chapter 3 - Label Design and Synthesis 
 
Through the synthesis of a range of electrochemically active molecular labels for 
DNA hybridisation probes, the aim was to facilitate detection of a number of analytes 
within the same amplification matrix.  The syntheses involved classic synthetic 
organic reactions including Wadsworth-Emmons olefination and amide couplings and 
whilst the synthetic procedures are presented herein in stages for simplicity, synthesis 
was performed in a continuous  process (i.e. starting material through to label) in 
order to afford the oligonucleotide labels.  Syntheses were, however, interrupted in 
order to analyse the potential electrochemistry of the compounds, as detailed in this 
chapter.  Characterisation, therefore, will be shown for the full molecular labels, as 
detailed on page 45. 
 
3.1 Synthesis of 5-Ferrocenylidene-2,2-dimethyl-1,3-dioxinane-4,6-dione                         
(Compound 1) and 5-Ferrocenyl-2,2-dimethyl-[1,3]dioxane-4,6-dione 
(Compound 2) 
 
Contemporary diagnostics often take advantage of biological / non-biological 
conjugates.  Among this type of compounds, metal-bearing nucleosides are one of the 
most important representatives of molecular hybrids as they can function as 
electrochemical and photoluminescent labels for nucleic acids, infrared labels, 
radioactive metal isotope carriers, active centres of DNA-directed artificial chemical 
nucleases, and metal-bearing components for the construction of probes for DNA-
mediated electron transfer
108
. 
 
Metal centres are usually attached to the nucleoside unit in the form of a metal 
complex, and complex-containing nucleoside conjugates are predominantly 
constructed by one of two major pathways: a) the synthesis of a chelator-containing 
nucleoside followed by metal complexation, and b) the synthesis of a functionalised 
nucleoside to which a metal complex can be conjugated, although in the majority of 
cases, chelators are used as vectors for metal ions.  One of the few exceptions is 
metallocene-type complexes, of which the best known example is ferrocene.  Only the 
second example of nucleoside-metallocene-type conjugates described thus far is the 
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nucleoside-metallacarborane modifications reported recently by Olejniczak et al.
 108 
in 
which the metallocarborane modification is attached to the nucleoside component in a 
unique type of reaction between a dioxane-metallocarborane adduct and a base-
activated nucleoside.  This method, which was originally demonstrated for thymine 
nucleoside followed by incorporation of the obtained conjugate into a DNA-oligomer, 
can be considered as a third, direct pathway for the synthesis of metal-complex-
containing nucleoside conjugates
108
.   
 
There has been thorough investigation into the factors affecting the redox potential of 
electrochemically active species, in particular, ferrocene.  Silva et al.
109
 studied the 
anodic behaviour of 34 ferrocene derivatives using cyclic voltammetry at at Pt 
electrode in an aprotic solvent.  Electron withdrawing and donating behaviour of 
various substituents were evaluated through their Hammett σp and Taft polar σ* 
constants and the half-wave oxidation potentials of the species were measured.  It is 
evident from this study that an increase in the electron-withdrawing ability of the 
substituent, as measured by the Hammett σp constant, is associated with an increase in 
the half-wave oxidation potential of the species. 
 
Silva‟s research later went on to report similar findings using disubstituted ferrocene 
moieties and proved successful in being predictive of a disubstituted species‟ anodic 
behaviour, using the Hammett constant σp of particular substituents
110
. 
 
Both studies indicated that the oxidation potential of ferrocene derivatives may be 
used as a probe in the study of the electronic properties of substituent groups, since 
their effects are transmitted through the carbocyclic ring to the iron redox active 
centre.  It is therefore intuitive that the oxidation potential of a ferrocene derivative 
may be engineered through exploitation of the electronic properties of substituent 
groups. 
 
An uncatalysed condensation reaction of 2,2-Dimethyl-1,3-dioxane-4,6-dione 
(Meldrum‟s acid) with Ferrocene carboxaldehyde was performed according to part of 
a reported clean synthesis in water by Bigi et al.
111
, to afford 5-Ferrocenylidene-2,2-
dimethyl-1,3-dioxinane-4,6-dione (Compound 1), as shown below (Scheme 2). 
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Scheme 2: The Synthesis of Compounds 1 and 2. 
 
Ferrocenecarboxaldehyde, as purchased from Lancaster Synthesis (Morecambe, 
Lancashire, UK.), (0.63g, 2.94mmol, 1.0 equiv) was added to a solution of Meldrum‟s 
acid from Sigma-Aldrich Ltd. (Gillingham, Dorset, UK.), (0.42g, 2.94mmol, 1.0 
equiv) in Milli-Q 0.22μm filtered water (Millipore - Billerica, Massachusetts, USA), 
(100mL) at room temperature.  The reaction mixture was allowed to stir for two hours 
at 75
o
C and the product was isolated by Buckner filtration, without further 
purification.  Yield: 51.6%; Rf = 0.49 (ethyl acetate/hexanes, 7:3); m/z 340.156; 
1
HNMR (300MHz, CDCl3): 1.5(6H, s), 4.05(5H, s), 4.65(2H, m), 5.0(2H, m), 
8.15(1H, s).   
 
Compound 1 (0.50g, 1.46mmol, 1.0 equiv.) was dissolved in absolute ethanol, as 
purchased from Sigma -Aldrich.  An excess of NaBH4 (Sigma-Adrich) was added 
carefully at room temperature and the mixture was stirred for 90 minutes at 55
o
C.  
The reaction was allowed to cool to room temperature and subjected to an extractive 
workup using diethylether and saturated NaCl, both purchased from Sigma-Aldrich.  
The diethyl ether was removed in vacuo, yielding 5-Ferrocenyl-2,2-dimethyl-
[1,3]dioxane-4,6-dione (Compound 2), as per Scheme 1.
 
Yield 98%; Rf = 0.46 (ethyl 
acetate/hexanes, 7:3); m/z 338.140; 
1
HNMR (300MHz, CDCl3): 1.5(6H, s), 4.05(5H, 
s), 3.25(2H, s), 3.6(1H, s), 4.05(2H, m), 4.15 (5H, m), 4.25(2H, s). 
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3.2. Electrochemical Analysis of the Oxidation Potential of Organic Substrates 
 
A 1mM solution of the compound was prepared in a phosphate buffered saline 
solution (PBS).  The PBS was prepared by addition of one PBS tablet from Sigma-
Aldrich Ltd. to 200mL of MilliQ filtered water, yielding 10mM phosphate buffer, 
2.7mM potassium chloride and 0.137M sodium chloride.  In order to aid solubility, 
the compound was firstly dissolved in 5mL of absolute ethanol from Fisher and hence 
made up to 50mL with the PBS, yielding a 10% Ethanol in PBS solvent. 
 
A low volume cell (LVC) from Bioanalytical Systems Instruments Ltd. (BAS) 
(Kenilworth, Warwickshire, UK) was employed (Figure 6). 
 
 
 
 
 
 
 
 
 
Figure 6: BAS Low Volume Cell.  Image courtesy of BAS. 
 
The LVC comprises of a freshly polished glassy carbon working electrode of 3mm in 
diameter, a gold wire counter electrode and a silver in 3M silver chloride reference 
electrode.  The LVC was coupled to an Autolab potentiostat PGSTAT12, from 
Autolab Electrical Instruments (Utrecht, The Netherlands) and the system 
subsequently coupled to a PC for analysis using Autolab software. 
 
With the cell vial and sample vial loaded with buffered solution and the electrodes in 
place (as per Figure 6), the differential pulse voltammogram was measured with the 
following potentiostat settings described in “Methods”. 
 
 
 
 
Teflon Cap 
                            Glassy Carbon Working 
Electrode 
                  Au  wire Counter 
Electrode 
Ag|AgCl Reference Electrode 
Cell Vial 
              Sample 
Vial 
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3.2.1 Electochemical Characterisation of 5-Ferrocenylidene-2,2-dimethyl-1,3-
dioxinane-4,6-dione (Compound 1) and 5-Ferrocenyl-2,2-dimethyl-[1,3]dioxane-
4,6-dione (Compound 2) 
 
It was envisaged that coupling ferrocene with Meldrum‟s acid would increase the 
oxidation potential of the iron centre, due to the electron withdrawing effect of the 
resultant conjugared system (as illustrated in Figure 7). 
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Figure 7:  TheElectron Withdrawing Effect of Resonance on the Ferrocene Unit. 
 
It was further envisaged that by simply reducing the alkene bond between the 
ferrocene moiety and the Meldrum‟s acid in 1, the electron withdrawing nature of the 
substituent would be lost as resonance would no longer be observed within the 
molecule, resulting in compound 2 (see Figure 8).  Furthermore, it was believed that 
the alkyl substituent would have an electron donating effect upon the carbocyclic 
system, resulting in a lower oxidation potential of the iron centre with respect to 
ferrocene (220mV). 
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Figure 8:  Loss of Rresonance by Reducing the alkene Between the Ferrocene Moiety and the 
Meldrum’s Acid. 
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Figure 9 shows the differential pulse voltammogram of a 1mM solution of compound 
1 in Phosphate Buffered Saline solution (PBS – inc. 10% EtOH). 
 
 
 
 
 
 
 
 
 
Figure 9: Differential Pulse Voltammogram of 1mM Compound 1 in PBS (inc. 10% EtOH) 
 
Figure 10 shows the differential pulse voltammogram of a 1mM solution of 
compound 2 in PBS (inc. 10% EtOH ). 
 
 
 
 
 
 
 
 
 
Figure 10: Differential Pulse Voltammogram of 1mM Compound 2 in PBS (inc. 10% EtOH). 
 
The electron withdrawing nature of the conjugated system observed in compound 1 
renders the ferrocene moiety of the molecule electron poor.  This is reflected in an 
oxidation potential of the Fe(II)/Fe(III) redox couple of 0.45V.  The loss of 
conjugation involved in compound 2, coupled with an electron donating effect from 
the alkyl substituent on the ferrocene, renders the ferrocene moiety of the molecule 
more electron-rich and thus more favourable to oxidation than compound 1; as 
reflected in the lower oxidation potential, with respect to ferrocene, of 0.05V. 
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3.3 Synthesis of (E)-3-Ferrocenyl-acrylic acid ethyl ester (Compound 3) and 3-
Ferrocenyl-propionic acid ethyl ester (Compound 4) 
 
The difference in electrochemical properties exhibited by compounds 1 and 2 render 
them potentially useful in a multiplex system owing to the difference in oxidation 
potential.  In order to afford labels for DNA probes based on this behaviour, 
compound 3 was prepared via Wadsworth-Emmons olefination between 
ferrocenecarboxaldehyde and triethylphosphonoacetate. In order to afford compound 
4, Compound 3 was subject to reduction using hydrogen with a palladium on 
activated carbon catalyst, purchased from Sigma-Aldrich Ltd, as illustrated in Scheme 
3. 
 
 
Fc OEt
O
H2, Pd/C, EtoH RT, 150 mins
Fc H
O
Fc OEt
O1) nBuLi, THF, 0oC, 2 mins, N2
2) (EtO)2POCH2CO2Et, THF, rt, 30 mins, N2
3) FcCHO, THF, rt, 15 mins, N2
Compound 3
Compound 4  
 
Scheme 3: Synthesis of Compounds 3 and 4. 
 
 
Triethylphosphonoacetate (0.86mL, 4.22mmol), as purchased from Sigma-Aldrich, 
was dissolved in dry THF and added via a dropping funnel to a solution of nBuLi 
(Sigma-Aldrich) (1.69mL, 4.22mmol) in dry THF (25mL) at 0
o
C under N2.  The 
reaction was then warmed to room temperature and allowed to mix for 30 minutes.  
Ferrocenecarboxaldehyde (0.78g, 3.52mmol) (Sigma-Aldrich) was dissolved in dry 
THF, which was subsequently added dropwise via a dropping funnel to the 
phosphonate ester anion solution.  The reaction mixture was stirred for a further 15 
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minutes to allow for completion of the reaction.  The solvent was removed in vacuo 
and the product was extracted using diethyl ether (30mL), as purchased from Sigma-
Aldrich, and MilliQ filtered water (30mL).  The aqueous layer was then re-extracted 
with diethyl ether (30mL).  The organic fractions were combined and dried using 
anhydrous magnesium sulphate and the solvent was removed in vacuo to yield 
Compound 3 without further purification. 
 
Compound 3 (500mg, 1.76 mmol) was dissolved in absolute Ethanol (20mL) and 10% 
catalytic amount of Palladium on activated carbon (0.19g, 0.18 mmol) was added.  
Hydrogen gas was then bubbled through the reaction mixture for five minutes and the 
mixture was allowed to stir for 150 minutes under a hydrogen atmosphere.  The 
reaction mixture was filtered over Celite 521 filter agent from Sigma-Aldrich Ltd to 
afford Compound 4 without further purification. 
 
3.3.1 Electochemical Characterisation of (E)-3-Ferrocenyl-acrylic acid ethyl ester 
(Compound 3) and 3-Ferrocenyl-propionic acid ethyl ester (Compound 4) 
 
In order to confirm the feasibility of compounds 3 and 4 as label precursors for 
multiplex DNA detection, esters 3 and 4 were each pre-dissolved in EtOH and diluted 
to 1mM in PBS.  The resultant solutions were then analysed using the BAS LVC.  
 
 
The differential pulse voltammogram of a 1mM solution of compound 3 is displayed 
in Figure 11. 
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Figure 11: Differential Pulse Voltammogram of 1mM Compound 3 in PBS (inc. 10% EtOH). 
 
 
The differential pulse voltammogram of a 1mM solution of compound 4 is displayed 
in Figure 12. 
 
 
 
 
 
 
 
 
 
Figure 12: Differential Pulse Voltammogram of 1mM Compound 4 in PBS (inc. 10% EtOH). 
 
The electron withdrawing nature of the conjugated system observed in compound 3 
renders the ferrocene moiety of the molecule electron poor.  This is reflected in an 
oxidation potential of the Fe(II)/Fe(III) redox couple of 0.3V.  The loss of conjugation 
involved in compound 4, coupled with an electron donating effect from the alkyl 
substituent, renders the ferrocene moiety of the molecule more electron-rich and thus 
more favourable to oxidation than compound 1; as reflected in the lower oxidation 
potential of 0.15V. 
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In order to establish whether compounds 3 and 4 had potential to fulfil the multiplex 
objective with greater confidence, a solution of 1mM of each ester in 10% EtOH in 
PBS was analysed electrochemically.  Figure 13 shows the differential pulse 
voltammogram of this multiplex solution. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Differential Pulse Voltammogram of 1mM Compound 3 and 1mM Compound 4 in PBS (inc. 
10% EtOH).  
 
Clear differentiation between the two label precursors is observed, showing potential 
use in a multiplexing system.  There is, however, an apparent decrease in the observed 
oxidation current for Ester 3, possibly due to instability of the alkene in the aqueous 
buffer together with the esters‟ partial insolubility in aqueous media.    
 
 
3.4 Synthesis of (E)-3-Ferrocenyl-acrylic acid (Compound 5) and 3-Ferrocenyl-
propionic acid (Compound 6) 
 
In order to activate the compounds, rendering them accessible for amide linkage to a 
linker moiety and phosphoramidite terminus, Esters 3 and 4 underwent base 
hydrolysis using sodium hydroxide to afford carboxylic acids, as shown in scheme 4. 
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Scheme 4: Base Hydrolysis of Esters 3 and 4, yielding carboxylic acids 5 and 6. 
 
To a solution of the ester 3 or 4 (1.3 mmol) in ethanol (25mL) was added NaOH 
(4.0mmol) (Sigma-Aldrich).  The solution was heated to 50
o
C and stirred for 18 
hours.  Acetic acid, as purchased from Sigma-Aldrich, was subsequently added to the 
reaction mixture to afford a solution pH of 6.5 (Fisherbrand Hydrus 300) and the 
product was extracted with DCM.  The organic phase was washed with brine 
(3x20mL) and MilliQ filtered water (3x20mL) and dried over MgSO4 (Sigma-
Aldrich).  The solvent was removed in vacuo to yield the product carboxylic acid 5 or 
6; which was used without further purification. 
 
 
3.5 Synthesis of (E)-N-(6-Hydroxy-hexyl)-3-ferrocenyl-acrylamide (Compound 7) 
and N-(6-Hydroxy-hexyl)-3-ferrocenyl-propionamide (Compound 8) 
 
The acids prepared (Compounds 5 and 6) were converted to the corresponding acid 
chlorides and further coupled with aminohexanol to afford compounds 7 and 8.  These 
compounds inherit an amide linker with an alcohol terminus available for further 
reaction with 2-cyanoethyldiisopropylchlorophosphoramidite; the attachment moiety 
for the 5‟ terminus of the oligonucleotide sequence of interest. 
 
OH
O
N
H
O
OH
1) Oxalyl chloride, DCM, 0
o
C - rt, 2h, N2
2) H2N(CH2)6OH, DCM, 0
o
C - rt, 2h, N2
R = FcC2H2   5
R = FcC2H4  6
R = FcC2H2   7
R = FcC2H4  8
R
R
 
Scheme 5: Synthesis of  7 and 8. 
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Oxalyl chloride (10.32mmol), as purchased from Sigma-Aldrich, in dry DCM (2ml) 
was added dropwise, using a pressure equalising dropping funnel, to a stirred 
suspension of carboxylic acid 5 or 6 (4.3mmol) in dry DCM (100mL) at 0
o
C under 
N2.  The reaction mixture was allowed to warm to room temperature and stirred for 2 
hours.  The solvent and remaining oxalyl chloride was carefully removed in vacuo.  
The acid chloride was then taken up in dry DCM (75mL) and 6-amino-hexan-1-ol 
(5.16mmol) (Sigma-Aldrich) in dry DCM (75mL) was added dropwise via a pressure 
equalised dropping funnel at 0
o
C under N2.  The reaction mixture was stirred for two 
hours whilst warming to room temperature.  The reaction mixture was washed with 
saturated NaHCO3 (1x100mL), then 1.0M HCl (1x100mL).  The organic layer was 
dried over MgSO4 and the solvent removed in vacuo.  The crude mixture was taken 
up in 50% EtOAC in petrol and filtered through a short silica pad in a sintered 
Büchner funnel capped with filter paper.  The pad was then washed with 500mL of 
50% EtOAc in petrol (Sigma-Aldrich) to remove any starting materials.  The pure 
product was then eluted from the pad using EtOAc to give the amidoalcohol (7 or 8) 
as a powder. 
 
3.5.1 Synthesis of 6-Diferrocenylamino-hexan-1-ol (Compound 9) and 6-
Ferrocenylamino-hexan-1-ol (Compound 10) 
 
In order to expand the potential range of phosphoramidite labels for use in the 
multiplex electrochemical system, a reductive amination of Ferrocenecarboxaldehyde 
using sodium triacetoxyborohydride was performed.  A differocenyl label was 
prepared as per an established synthesis by Flower
112 
(scheme 6) and a 
monoferrocenyl analogue was also synthesised to complement the range of 
monoferrocenyl labels already prepared. 
 
 
Fc O NH2 OH
NaBH(OAc)3
THF
Fc N
Fc
OH
n
n=6
n
n=6
 
Scheme 6: Synthesis of 6-Diferrocenylamino-hexan-1-ol (Compound 9) and 6-Ferrocenylamino-hexan-
1-ol (Compound 10) 
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Aminohexanol (1.00eq.) and sodium triacetoxyborohydride (3.00eq.) were added to 
Ferrocenecarboxaldehyde [(3.00eq.) for compound 9 (1.5eq.) for compound 10] in dry 
THF and the reaction mixture was stirred under N2 for 12 hours at room temperature.  
1M sodium hydroxide  (4 eq. To NaBH(OAc)3) and ethyl acetate of equal volume was 
added and the mixture was separated.  The organic layer was washed with sat. 
NaHCO3, sat. NaCl and H2O and subsequently dried over MgSO4.  The solvent was 
removed in vacuo. 
 
The crude product was purified via flash chromatography (SiO2, 40% ethyl acetate, 
60% petroleum ether (40-60
o
C) +5% triethylamine. 
 
3.5.2 Synthesis of N-(6-Hydroxy-hexyl)-ferrocenamide (Compound 11) 
 
Compound 11 was synthesised as per Scheme 7 in order to compliment the range of 
phosphoramidite precursors already prepared (compounds 7-10). 
 
 
 
OH
O
N
H
O
OH
1) Oxalyl chloride, DCM, 0
o
C - rt, 2h, N2
2) H2N(CH2)6OH, DCM, 0
o
C - rt, 2h, N2
R = Fc R = Fc   11
R
R
 
Scheme 7: Synthesis of N-(6-Hydroxy-hexyl)-ferrocenamide (Compound 11) 
 
Oxalyl chloride (10.32mmol) in dry DCM (2ml) was added dropwise, using a 
pressure equalising dropping funnel, to a stirred suspension of ferrocenecarboxylic 
acid in dry DCM (100mL) at 0
o
C under N2.  The reaction mixture was allowed to 
warm to room temperature and stirred for 2 hours.  The solvent and remaining oxalyl 
chloride was carefully removed in vacuo.  The acid chloride was then taken up in dry 
DCM (75mL) and 6-amino-hexan-1-ol (5.16mmol) in dry DCM (75mL) was added 
dropwise via a pressure equalised dropping funnel at 0
o
C under N2.  The reaction 
mixture was stirred for two hours whilst warming to room temperature.  The reaction 
mixture was washed with saturated NaHCO3 (1x100mL), then 1.0M HCl (1x100mL).  
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The organic layer was dried over MgSO4 and the solvent removed in vacuo.  The 
crude mixture was taken up in 50% EtOAC in petrol and filtered through a short silica 
pad in a sintered Büchner funnel capped with filter paper.  The pad was then washed 
with 500mL of 50% EtOAc in petrol to remove any starting materials.  The pure 
product was then eluted from the pad using EtOAc to give the amidoalcohol as a 
powder. 
 
 
3.6 Synthesis of (Label JAOL1), (Label JAOL2), (Label JAOL3), (Label JAOL4) 
& (Label JAOL5) 
 
Table 1 shows the corresponding Label name for an individual phosphoramidite 
precursor (Compound 7, 8, 9, 10 & 11). 
 
Compound Corresponding Label Name 
7 LabelJAOL2 
8 LabelJAOL3 
9 LabelJAOL4 
10 LabelJAOL5 
11 LabelJAOL1 
Table 1 – Corresponding Label Names 
 
N,N-Diisopropylethylamine (8.4mmol) was added to a stirred solution of the 
amidoalcohol (7, 8, 9, 10 or 11) (2.1mmol) in dry THF (25mL) under nitrogen.  2-
Cyanoethyldiisopropylchlorophosphoramidite (3.15 mmol) (Sigma-Aldrich) was 
added dropwise and the reaction stirred for 15 minutes.  MilliQ filtered water (200μL) 
was added and the reaction stirred for a further 30 minutes.  Ether – triethylamine 
(50/50, 25mL) (sigma-Aldrich) was added and a precipitate formed.  The mixture was 
washed with saturated NaHCO3 (25mL), then MilliQ filtered water (25mL).  The 
organic layer was then dried over MgSO4 and the solvent removed in vacuo.  
Purification by flash chromatography (SiO2, 60% EtOAc/petrol + 1% Et3N) gave the 
phosphoramidite (JAOL1, JAOL2, JAOL3, JAOL4 & JAOL5) as an oily liquid. 
 
The phosphoramidites were stored at –20oC, under nitrogen. 
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Label Characterisation 
 
LabelJAOL1 
Yield: 54%, Rf: 0.15 (ethylacetate/hexanes, 7:3), m/z: 529.45, 
1
HNMR (300MHz, 
CDCl3): 6.06(1H, br. m, NH), 4.66(2H, ap. S, H-cp), 4.27 (2H, ap.s, H-cp), 4.14(5H, 
s, H-cp‟), 3.83(2H, dd, J 13.2, 6.9), 2.65(2H, t, 6.4), 1.56-1.00 (20H, m), 31PNMR 
(121.5MHz, CDCl3): 147.9 (s). 
 
LabelJAOL2 
Yield: 57%, Rf: 0.14 (ethylacetate/hexanes, 7:3), m/z: 559.5, 
1
HNMR (300MHz, 
CDCl3): 7.39(1H, d), 5.90(1H, d), 5.42(1Hbr. M, NH), 4.37(2H, ap.s, H-cp), 4.29(2H, 
ap.s, H-cp), 4.08(5H, s, H-cp‟), 3.75(2H, ap. m), 3.55(2H, ap. m), 3.55(1H, ap. m), 
3.26(2H, q), 2.57(2H, t), 1.35(20H, ap. m), 
31
PNMR (300MHz, CDCl3): 147.9 (s). 
 
LabelJAOL3 
Yield: 56%, Rf: 0.20 (ethylacetate/hexanes, 7:3), m/z: 557.5, 
1
HNMR (300MHz, 
CDCl3): 5.30(1H, br. M, NH), 4.03(5H, s, H-cp‟), 3.97(2H, ap. m, H-cp), 3.75(2H, ap. 
m), 3.60(3H, ap. m), 3.15(2H, ap.q), 2.62(4H, m), 2.23(2H, t), 1.4(20H, ap. m), 
31
PNMR (300MHz, CDCl3): 147.9 (s). 
 
LabelJAOL4 
Yield: 54%, Rf: 0.7 (ethylacetate/hexanes, 7:3), m/z: 529.3, 
1
HNMR (300MHz, 
CDCl3): 6.06(1H, br.m, NH), 4.66 (2H, ap. s, H-cp), 4.27 (2H, ap. s, H-cp), 4.14 (5H, 
s, H-cp‟), 3.83 (2H, m), 3.57 (4H, m), 3.28 (2H, dd, J 13.2), 2.65 (2H, t, J 6.4), 1.56-
1.00 (20H, m), 
31
PNMR (300MHz, CDCl3): 147.9 (s). 
 
LabelJAOL5 
Yield: 37%, Rf: 0.8 (ethylacetate/hexanes, 7:3), m/z: 727.36, 
1
HNMR (300MHz, 
CDCl3): 4.1(4H, s), 4.05(4H, s), 4.01(8H, m), 3.7(1H, m), 3.5(2H, m), 3.3(1H, ap. q), 
2.6(1H, ap. t), 1.55-1.00(20H, m), 
31
PNMR (300MHz, CDCl3): 147.9 (s). 
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3.7 Probe Manufacture – Probes JAOL1, JAOL2, JAOL3, JAOL4 & JAOL5 
 
Labels JAOL1, JAOL2, JAOL3, JAOL4 and JAOL5 were then attached to the 5‟ end 
of a specified oligonucleotide recognition sequence using standard solid phase 
coupling and reverse phase HPLC purification (atdBio, Southampton, UK), to afford 
labelled probe oligonucleotides, as exemplified in Scheme 8.  
 
11, 12 and 13
N
NN
N
NH2
O
OHO
HH
HH
OP-O
O-
O
N
H
O
R
Gene sequence
5'
3'
Adenine
 
 
Scheme 8: Solid Phase Coupling of Phosphoramidite to Target DNA. 
 
Labelling of synthetic oligonucleotides during solid-phase synthesis has the advantage 
that large quantities of labelled oligonucleotide can be prepared for major applications 
such as DNA diagnostics and forensic screening.  The simplest way to label an 
oligonucleotide during solid-phase synthesis is to add the chemical modification to 
the 5‟-end, although 3‟-labelling and internal labelling is also possible using special 
phosphoramidite monomers.  The addition of labels to amino- or thiol-modified 
oligonucleotides after solid-phase synthesis is less efficient and requires less care.  
Labelling a deoxy- or dideoxynucleoside triphosphate and incorporating the monomer 
using DNA polymerisation is an enzyme-catalysed procedure and is therefore a small 
scale method.  However, it is a convenient technique for introducing a large number 
of labels into a DNA strand. 
 
The labelled-oligonucleotide is further subject to reverse-phase HPLC purification. 
 
 
Table 2 indicates the oxidation potential of each probe in PBS (including 10% EtOH) 
vs. Ag¦AgCl. 
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Probe Name Eox vs. Ag¦AgCl (mV) 
JAOL1 0.315 
JAOL2 0.200 
JAOL3 0.075 
JAOL4 0.200 
JAOL5 0.200 
Table 2: Corresponding probe names to oxidation potential 
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Chapter 4 – Methods 
 
4.1 – Differential Pulse Voltammetry 
 
Throughout the scope of this thesis, all solutions of redox species contain background 
electrolyte in form of salts inherent in the buffers used and as such, the systems are 
described as being diffusion limited.  The current-time response for the Faradaic 
process is described by the Cotrell equation (Equation 1): 
 
 
t
DOnFA
i


 
Equation 1: The Cotrell Equation.   n is the number of electrons, F is Faraday‟s constant, A is the 
electrode area, [O] is the bulk concentration of oxidised species, D is the diffusion constant. 
 
Following a potential step, the Faradaic current decays at a rate proportional to 1/t
1/2
.  
Charging current, however, is also part of the total measured current and is 
proportional to e
-t
.  The Faradaic current, therefore, decays more slowly than the 
charging current.  This is important, as the Faradaic current is directly proportional to 
the concentration of the electroactive ferrocene moiety (by the Cotrell equation – 
Equation 1), but the charging current is largely independent of the concentration of 
the electroactive species.  In the systems under investigation, the concentrations of 
electroactive species are low, and as a result, the Faradaic current are also very low 
(nA – μA).  The consequence of this is that the capacitive current may have distorted 
the measured values, leading to inaccuracies in the measurement.  The solution to this 
problem is to use Differential Pulse Voltammetry. 
 
Differential Pulse Voltammetry involves applying a potential step, waiting for some 
time (generally milliseconds), and then measuring the current.  By waiting, the 
capacitive charging current will have decayed to very small amounts, but the Faradaic 
current will still be significant.  In addition, the differential current is measured – that 
is the difference in current before the pulse and some time after the pulse.  Thus, the 
application of a pulse sequence and the sampling of the current at some point before 
and at the end of the pulse can remove the effects of capacitive charging (Figure 14). 
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Figure 14: Representation of Differential Pulse sequence. E is potential (V) and t is time. Image 
courtesy of the University of Bath. 
 
Throughout, the electrochemical cell was coupled to an Autolab potentiostat 
PGSTAT12, from Autolab Electrical Instruments (Utrecht, The Netherlands) and the 
entire system coupled to a PC for analysis.   
 
The potentiostat settings described below were adopted for all analyses unless 
specified) herein. 
 
Pretreatment: Conditioning potential (V): 0, Duration: 0s, Deposition potential: 0, 
Duration: 0, Equilibration time: 0, Measurement: Cell of after measurement: X, 
Modulation time(>=0.0025): .04, Interval time (>=0.105): .1, Potentials: Initial: -
0.1, End: 0.5, Step: 0.003, Modulation amplitude: 0.04995, Standby potential (V): 0. 
 
3.2 – DPV Measurement, using Screen Printed Carbon Electrodes (SPCEs) 
 
Electrochemical Analyses were performed on screen printed carbon electrodes 
(SPCEs), as purchased from Gwent Electronic materials (GEM) (Pontypool, Wales, 
UK), using the parameters detailed. 
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The screen-printing technology is widely used for the mass-production of disposable 
electrochemical sensors.  The practical utility of screen-printed electrodes has been 
developed despite the fact that little is known about the nature of electrode reactions 
at these important microfabricated sensors
113
.  The screen-printing microfabrication 
technology is commonly used for large-scale production of extremely inexpensive and 
yet highly reproducible electrochemical sensors 
114-116
.  Screen-printed sensors are 
expected to be widely used in numerous real-life applications of controlled potential 
techniques, and are already the devices of choice for the commercialisation of “one-
shot” glucose117 or metal118 sensors. 
 
 
The SPCEs used herein comprised of a central counter electrode 
(carbon graphite ink): 0.25mm X 6mm, an outer working electrode 
(carbon graphite ink): 0.5mm wide and the spacing between the 
electrodes was 0.375mm.  The reference electrode comprised of a 
0.5mm square (silver/ silver chloride paste). 
 
The electrodes were manufactured on a Valox backing polymer; 
which has desirable inherent dielectric properties. 
 
20μL samples for analysis were applied to the surface of the electrode, ensuring that 
the reference electrode, as well as the working and counter electrodes were covered. 
Owing to the hydrophobic interaction of the aqueous samples with the polymeric 
electrode coating, this often required manipulation of the sample using a sterile 
pipette tip.  
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4.2 –  DNA Sequences 
 
All sequences referred to herein are noted 5‟-3‟.  Unless specified, all synthetic targets 
and primers were purchased from Sigma Genosys (Gillingham, Dorset, UK). All 
DNA probes were purchased from ATDBio (University of Southampton, UK).  
 
N. gonorrhoeae 
 
Synthetic Target: 
TATTGTGTTGAAACACCGCCCGGAACCCGATATAATCCGCCCTTCAACATC
AGTGAAAATCTTTTTTTAAC 
 
The red section is the recognition sequence for the hybridisation probe and the primer 
sequences are as follows: 
 
Primer sequences: 
NgF1 (Forward Primer): GTTGAAACACCGCCCGG 
NgR1 (Reverse Primer): CGGTTTGACCGGTTAAAAAAAGAT 
 
Genomic Target: 
Neisseria gonorrhoeae genomic DNA was purchased from LGC Promochem (United 
Kingdom) and used at 10μg/mL. 
 
C. trachomatis 
 
The following sequences were identified for use by Atlas Genetics Ltd. and form part 
of the cryptic plasmid. 
 
Synthetic Target: 
CGCAGCTGCTGTAATCACCCAGTCGATAAATGTGTAAGCATACTTTGATG
CATTTGGGAAGCGCATTTTTATTTCTTAATATACATTTGCAGGCTTGATTA
CAAAGTAGGATTCTATTTGATCTACCAAGATAGGACATGGCTCTACAACG
AACCC 
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The red section is the recognition sequence for the hybridisation probe and the primer 
sequences are as follows: 
 
Primer Sequences: 
CHF3 (Forward Primer): GGGTTCGTTGTAGAGCCATGT 
CHR4 (Reverse Primer): CGCAGCTGCTGTAATCACC 
 
Genomic Target: 
Chlamydia trachomatis E (BOUR Strain) Elementary Bodies were used at a 
concentration of ~8x10
7
 EB‟s/mL, as purchased from USBiological (Massachusetts, 
USA). 
 
β-Actin 
 
The following sequences were identified for use by Atlas Genetics Ltd. and form part 
of the human β-actin gene. 
 
Synthetic Target: 
CCAGCCAGGTCCAGACGCAGGATGGCATGGGGGAGGGCATACCCCTCGT
A 
 
The red section is the recognition sequence for the hybridisation probe and the primer 
sequences are as follows: 
 
Primer Sequences: 
BAF3 (Forward Primer): TGAAGCTGTAGCCGCGCTCGGT 
BA4 (Reverse Primer): TCACCCACACTGTGCCCATCTACGA 
 
Genomic Target: 
A synthetic target was used for genomic assays, as purchased from Sigma Genosys. 
 
 
 
 
 
 53 
4.3 – Amplification of Gene Targets using PCR 
 
 
4.4.1: Uniplex PCR 
 
For a uniplex PCR (one that amplifies a single DNA sectional sequence), the 
following generic PCR „recipe‟ outlined below was applied. 
Reagent Volume (µL) 
10xPCR Buffer (GE – Chalfont St Giles, Buckingham, UK) 2 
1.5mMdNTPs (Promega – Southampton, UK) 2 
10μM Primer Forward (Sigma Genosys – Gillingham, Dorset, UK) 1 
10μM Primer Reverse (Sigma Genosys) 1 
5000UmL
-1
Taq Polymerase (GE) 0.2 
25mM MgCl2 (GE) 1.2 
Target DNA 2 
H2O (Sigma Aldrich – Gillingham, Dorset, UK) 10.6 
Total 20 
Table 3: Reagent Volumes for a uniplex PCR 
 
Using a DNA Engine from MJ Research (now Bio-Rad) (Hemel-Hempstead, 
Hertfordshire), with the following cycling parameters were employed to amplify the 
target DNA: 
 
1=94.0
o
C for 1:00 
2=94.0
o
C for 0:20 
3=60.0
o
C for 0:20 
4=72.0
o
C for 0:20 
5=GOTO2, 39 times 
6=72.0
o
C for 3:00 
7=4.0
o
C for ever 
8=END 
This cycling program shall herein be referred to as “BACTIN3”. 
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4.4.2 Duplex PCR 
 
For a duplex PCR (one that amplifies two DNA sectional sequences), the following 
generic PCR „recipe‟ outlined below was applied. 
 
Reagent Volume (µL) 
10xPCR Buffer (GE – Chalfont St Giles, Buckingham, UK) 2 
1.5mMdNTPs (Promega – Southampton, UK) 2 
10μM Primer FSequence 1 (Sigma Genosys – Gillingham, Dorset, UK) 1 
10μM Primer RSequence 1 (Sigma Genosys) 1 
10μM Primer FSequence 2 (Sigma Genosys) 1 
10μM Primer RSequence 2 (Sigma Genosys) 1 
5000UmL
-1
Taq Polymerase (GE) 0.2 
25mM MgCl2 (GE) 1.2 
Sequence 1 Target DNA 2 
Sequence 2 Target DNA 2 
H2O (Sigma Aldrich – Gillingham, Dorset, UK) 6.6 
Total 20 
Table 4: Reagent Volumes for Duplex PCR 
Thermal cycle BACTIN3 was used to amplify the target sequences. 
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4.4.3 Triplex PCR 
 
For a triplex PCR (one that amplifies three DNA sectional sequences), the following 
generic PCR „recipe‟ outlined below was applied. 
 
 Chlamydia Gonorrhoea β-actin Triplex 
Reagent Volume 
(µL) 
Volume (µL) Volume 
(µL) 
Volume 
(µL) 
10xPCR Buffer (GE – Chalfont St Giles, 
Buckingham, UK) 
2 2 2 2 
1.5mMdNTPs (Promega – 
Southampton, UK) 
2 2 2 2 
10μM Primer FCHL (Sigma Genosys – 
Gillingham, Dorset, UK) 
1 1 1 1 
10μM Primer RCHL (Sigma Genosys) 1 1 1 1 
10μM Primer FNG (Sigma Genosys) 1 1 1 1 
10μM Primer RNG (Sigma Genosys) 1 1 1 1 
10μM Primer Fβ-A (Sigma Genosys) 1 1 1 1 
10μM Primer Rβ-A (Sigma Genosys) 1 1 1 1 
5000UmL
-1
Taq Polymerase (GE) 0.2 0.2 0.2 0.2 
25mM MgCl2 (GE) 1.2 1.2 1.2 1.2 
8.5x10
-7
 EBmL
-1
 DNACHL (US Biological 
– Swampscott, Massachusetts, USA) 
2 0 0 2 
10µgmL
-1
 DNA NG (ATCC – Manassas, 
VA, USA) 
0 2 0 2 
10nM DNAβ-Actin (Sigma Genosys) 0 0 2 2 
H2O (Sigma Aldrich – Gillingham, 
Dorset, UK) 
6.8 6.8 6.8 2.6 
Total 20 20 20 20 
Table 5: Reagent Volumes for Individual and Triplex PCR of Genomic Targets: Chlamydia 
trachomatis, Neisseria gonorrhoeae and Human β-actin. 
 
Thermal cycle BACTIN3 was used to amplify the target sequences. 
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4.4 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis is a method used in biochemistry and molecular biology 
to separate DNA, or RNA molecules by size. This is achieved by moving negatively 
charged nucleic acid molecules through an agarose matrix with an electric field 
(electrophoresis). Shorter molecules move faster and migrate further than longer 
ones
125 
.  All gels herein were prepared by dissolving agarose (Sigma-Aldrich) under 
microwave heat in 0.5% TBE (Tris/Borate/EDTA) buffer at 3% w/v.  To 100mL of 
the resultant gel solution, 10µL of 10mg/mL ethidium bromide was added.  The 
resultant mixture was poured into a gel tank with gel combs in place to produce wells 
upon setting.  Once the gel had set, 10µL of the PCR product was added to 2µL of 6x 
Loading dye (Promega) and the PCR product was introduced into the wells and the 
gel was subject to 100V potential difference in 0.5x TBE.   
 
4.5 UV Visualisation of gel product 
 
The most common dye used to make DNA or RNA bands visible for agarose gel 
electrophoresis is ethidium bromide, usually abbreviated as EtBr. It fluoresces under 
UV light when intercalated into DNA (or RNA). By running DNA through an EtBr-
treated gel and visualizing it with UV light, any band containing more than ~20ng 
DNA becomes distinctly visible and an image can be taken.  This procedure for gel 
visualisation is used herein. 
 
4.6 T7 Exonuclease Electrochemical assay using amplicon product  
 
To 20µL of the PCR product, 1µL of each probe [CHL3 (75mV), Ng14-151(1:10) 
(200mV) and BA1(315mV)] was added, followed by 2µL of T7 exonuclease and the 
matrix incubated as per “Inc-J program” (37oC for 20 minutes, followed by cooling to 
16
o
C).  The sample was then loaded onto a SPCE for analysis and electrochemical 
measurement was subsequently performed.  
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4.7 DNA Amplification from Clinical Samples 
 
Clinical samples were obtained from Dr. Clare Ling, Dept. Virology at the Royal Free 
Hospital in London, UK.  The samples were anonymous discard samples, which had 
been tested using a culture assay for Neisseria gonorrhoeae and using the BD 
Probetec
TM
 protocol for Chlamydia trachomatis.  The BD ProbeTec Chlamydia 
trachomatis amplified DNA assay is based on the simultaneous amplification and 
detection of target DNA using amplification primers and a fluorescently labelled 
detector probe. The strand displacement amplification (SDA) reagents are dried in 
two separate disposable microwell strips. The processed sample is added to the 
Priming Microwell which contains the amplification primers, fluorescently labelled 
detector probe, and other reagents necessary for amplification. After incubation, the 
reaction mixture is transferred to the Amplification Microwell, which contains two 
enzymes (a DNA polymerase and a restriction endonuclease) necessary for SDA.  The 
Amplification Microwells are sealed to prevent contamination and then incubated in a 
thermally controlled fluorescent reader which monitors each reaction for the 
generation of amplified products. The presence or absence of CT is determined by 
relating the BD ProbeTec MOTA (Method Other Than Acceleration) scores for the 
sample to pre-determined cut-off values. The MOTA score is a metric used to assess 
the magnitude of signal generated as a result of the reaction. 
 
The patient samples provided were 8 tested negatives for C. trachomatis and 6 tested 
positives for C. trachomatis.  All patients, however, were confirmed as negative for N. 
gonorrhoeae.  Using the BD ProbeTec protocol, patient samples, whether they are 
urine or in a swab elution buffer, were initially centrifuged for thirty minutes at 2000 
g and the supernatant carefully decanted in order to minimize any inhibition of the 
amplification stage.  The samples were then lysed at 114
o
C.  Of each patient, two sub-
samples were provided, one lysed and one unlysed.  The lysed samples in each case, 
were used in the assay in order to improve amplification. 
 
Table 6 indicates patient numbers for the samples provided, including the result of 
their analysis at the Royal Free Hospital. It should be noted that the assay was 
performed „blind‟. It was not until later discussion with the RFH that the veracity of 
our assay was established. 
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Samples Typed Negative for C. trachomatis 07M195165 
07M195167 
07M195175 
07M195172 
07M195180 
07M195179 
07M195178 
07M195176 
Samples Typed Positive for C. trachomatis 07M194999 
07M195129 
07M195831 
07M195139 
07M195123 
07M195149 
Table 6: Sample Identification 
 
PCR was performed using the recipe described below (Table 7).  BACTIN3 was the 
amplification program used and PCR negative controls were performed using sigma 
water in lieu of clinical sample. 
 
 Triplex 
Reagent Volume (µL) 
10xPCR Buffer (GE – Chalfont St Giles, Buckingham, UK) 3 
1.5mMdNTPs (Promega – Southampton, UK) 3 
10μM Primer FCHL (Sigma Genosys – Gillingham, Dorset, UK) 0.3 
10μM Primer RCHL (Sigma Genosys) 0.3 
5000UmL
-1
Taq Polymerase (GE) 0.3 
25mM MgCl2 (GE) 1.8 
BD Probec Sample  (Royal Free Hospital – London, UK) 2 
H2O (Sigma Aldrich – Gillingham, Dorset, UK) 19.3 
Total 30 
Table 7: PCR Components for Clinical Sample PCR 
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4.8 T7 Exonuclease Electrochemical assay using amplicon from clinical sample 
PCR 
 
The PCR product from the methodology described in section 4.7 was subject to 
agarose gel electrophoresis and UV visualisation and electrochemical analyses were 
performed as per sections 4.4 and 4.5. 
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Chapter 5 - Electrochemical Mechanisms of Assay Discrimination 
 
5.1: DNA adsorption to Electrode Surfaces 
  
DNA adsorption is fundamental to many biological functions, notably in human 
pathology
126
.  Adsorption occurs via a number of pathways, though primarily through 
electrodiffusive processes.  Recent research has investigated rate-limiting steps of 
DNA adsorption and the factors affecting it.  Nguyen et al., for example, have 
investigated the role of divalent cations in plasmid DNA adsorption to natural organic 
matter-coated silica surfaces
126
. 
 
DNA adsorption to inorganic surfaces, notably electrodes, has also been the focus of 
intense research.  Xu et al.modified ss-DNA and ds-DNA onto the surface of two 
silanized indium tin oxide (ITO) electrodes through means of adsorption, respectively, 
and were found to have gained high concentration after being electrochemically 
characterised.  The electrode, modified by ss-DNA, recognised the complementary ss-
DNA in solution with good repeatability
121
.  Much work has also been invested in 
researching techniques for investigating oxidative damage to DNA at electrode 
surfaces.  Ferapontova et al. studied electrochemically induced oxidative damage to 
DNA with ds calf thymus DNA immobilized directly on a gold electrode surface via 
adsorptive processes
121
. 
 
With electrochemistry at phase boundaries becoming more interesting to research 
endeavours, Osakai et al. have recently exploited adsorbed DNA on a polarized 1,2-
dichloroethane/water interface as a facilitator for cationic-surfactant transfer.  The 
voltammetric behaviour of the DNA was investigated and the peak current obtained 
showed a Langmuir-type dependence on the DNA
122
.  
 
5.2: Differential Pulse Analysis 
 
The electrochemical assay described herein is configured to yield a peak current for 
an electrochemically labelled moiety.  As stated in the Introductory chapter, the 
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labelled moiety released post T7 exonuclease digest exhibits a higher peak oxidation 
current than an undigested probe. 
 
Figure 16 displays the differential pulse voltammogram (DPV) response for a fully 
complementary probe – target sequence for Chlamydia (Methods), labelled with 
Probe JAOL3 (Label Design and Synthesis).  A clear difference In peak current 
between the probe-target + T7 exonuclease and the two control measurements: 
complementary probe-target with heat deactivated T7 exonuclease and probe without 
target is clearly observed. 
 
 
Figure 16: Chlamydia Exonuclease Assay 
 
The basis of the observed discrimination between the peak oxidation currents for the 
probe-target + T7 and probe-no target + T7 exonuclease matrices was initially 
attributed to differences in diffusion coefficient of the enzymatically-digested 
electrochemically-labelled moiety and the labelled oligonucleotide probe.  Further 
investigation, however, suggests a more subtle explanation for the observed 
behaviour. 
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5.3: Mass Spectral Analysis 
 
A fundamental point in gaining better understanding of the mechanism of assay 
discrimination is the elucidation of the structure of the digest product released and 
detected at the electrode. 
 
The mechanism of action of the gene 6 exonuclease of bacteriophage T7 has been 
thoroughly investigated
123
 The enzyme hydrolyzes duplex
 
DNA until about 50% of 
the DNA is classed as acid soluble. The remaining
 
acid-insoluble DNA is single 
stranded and the acid-soluble product
 
is almost entirely 5'-mononucleotides. The 
enzyme begins its
 
exonucleolytic attack at the 5' terminus of DNA and hydrolyzes
 
5'-
phosphoryl terminated and 5'-hydroxyl terminated DNA at equal
 
rates. The 
exonuclease releases a dinucleoside monophosphate
 
from a 5'-hydroxyl terminus and 
is able to release from one
 
chain of DNA and begin hydrolysis of another before 
completion
 
of hydrolysis. The enzyme is able to initiate hydrolysis at
 
nicks as well as 
at external termini
123
. 
 
Figure 17, below, illustrates the T7 exonuclease assay used within the scope of this 
thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Outline of the T7 Exonuclease Assay 
 
Target DNA amplification 
Probe oligonucleotide 
addition 
T7 exonuclease incubation 
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In the research carried out and described here, the 5‟ terminus of the probe duplex in 
this assay possessed a ferrocene-based moiety, mass-spectral analyses were performed 
in order to elucidate the composition of the digest fragments produced post-digestion 
in the enzymatic assay.  The identifier sequence of the CTR gene (20 bases) for 
Neisseria meningitides was selected as the candidate for this study and the digest 
performed as described in “Methods”.  Label JAOL4 was attached to not only the 
probe sequence in this case, but to a separate mononucleotide, on the 5‟ base of the 
probe sequence (A) (as illustrated in Table 8) and to a separate base dinucleotide, on 
the two 5‟ bases of the probe sequence (AT).   
 
Table 8: Base Labelling of Label JAOL4. 
 
The labeled mononucleotide and dinucleotide were hence used as molecular markers 
for the two potential digest fragments of T7 exonuclease.  The analyses were 
performed on a micrOTOF mass spectrometer, using Bruker Daltronics data anaysis.  
Figure 18 displays the spectrum for the labelled mononucleotide and dinucleotide, 
each exhibiting peaks at their theoretical masses; [M-H]
-
=863 and [M-H]
-
=1167 
repectively. 
N O P O 
O 
O 
N 
N N 
N 
N H 2 
O 
H O 
H H 
H H 
F e 
A d e n i n e 
F e 
P 
O H 
O 
H O 
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Figure 18: Mass Spectral analysis of the synthesised markers 
 
The CTR gene probe and its complementary target were incubated with T7 
exonuclease,  and a mass-spectral analysis of the post-digest mixture was performed 
without further purification.  The result of this analysis is displayed in Figure 19. 
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Figure 19: Mass Spectral analysis of the digest product 
 
 
The single peak at m\z = 863 [M-H]
-
 confirms that the electrochemical moiety, 
released to the electrode is in fact the labeled mononucleotide, with the enzymatic 
release of no labeled dinucleotide upon incubation of the assay matrix. 
 
Figure 20 shows the DPV response for a fully complementary probe – target sequence 
for N. gonorrhoea labelled with probe BA probe, JAO2. The clear difference in peak 
current between the complementary probe-target and the probe without target can be 
clearly observed. The DPV response of a single nucleotide labelled with the same 
ferrocene label as in figure 20 was measured and is shown in figure 21, with a very 
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similar response being measured. Mass spectrometry of the T7 digested probe-target 
sequence also confirmed that a single nucleotide ferrocene was released. Evidently the 
electrode discriminates between a ferrocene labelled mononucleotide and the 
ferrocene labelled oligonucleotiode. The question that remains is what is the 
mechanism of discrimination? 
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Figure 20: Neisseria gonorrhoeae digest Figure 21: Single nucleotide labelled 
 
 
The discrimination between mono nucleotide ferrocene and oligonucleotide ferrocene 
was originally attributed to differences in the diffusion coefficient of the ferrocene 
labelled mono-nucleotide compared with the labelled oligo‟.  However, we now think 
that this explanation may be false, and more a more subtle explanation accounts for 
the observed behaviour.  
 
 
5.4: Cyclic Voltammetric Analysis 
Cyclic voltammetry was employed as an electroanalytical tool to probe the processes 
occurring at the electrode.  Screen printed carbon electrodes (SCPEs) from Gwent 
Electronic Materials Ltd. (GEM) (Pontypool, UK) were employed for electrochemical 
analysis.  The GEM electrodes comprise of screen-printed carbon working and 
counter electrodes and a silver chloride paste reference electrode upon a valox
®
 
backing plastic.  
 
The CTR gene JAOL4 probe and its complementary target were incubated with T7 
exonuclease, as per “Methods” and cyclic voltammetry of the digest product yielded 
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the results illustrated in figure 22a and 22b.  The linear relationship between peak 
current and scan rate is highly indicative of an adsorption controlled electron transfer 
mechanism and not a diffusion controlled scenario, as initially believed
124
. 
 
-0.1 0.0 0.1 0.2 0.3 0.4 0.5
-2.0x10
-6
-1.0x10
-6
0.0
1.0x10
-6
2.0x10
-6
3.0x10
-6
C
u
rr
e
n
t 
/ 
A
Potential / V
 500 mV s
-1
 400 mV s
-1
 300 mV s
-1
 200 mV s
-1
 150 mV s
-1
 100 mV s
-1
 50 mV s
-1
 20 mV s
-1
 10 mV s
-1
 
0 100 200 300 400 500
0
500
1000
1500
2000
2500
3000
R
2
 = 0.9960
I p
 /
 n
A
Scan rate / mV s
-1
 Anodic scan
 Cathodic scan
 
R
2
 = 0.9987
 
22a 22b  
Figure 22: Evidence of an adsorption-controlled electron transfer mechanism. 
 
 
Figure 23 displays the results from a study of the non-digested Labelled CTR 
JAOL4probe, indicating linear dependence of peak oxidation current on the cyclic 
voltmmetry scan rate, as per figure 22.  In this case, however, the peak oxidation 
currents are a factor of five lower for the same scan rate, suggesting restricted electron 
transfer from the adsorbed electrochemically Labelled probe to the electrode.  Cyclic 
voltammograms for both the digested and undigested probes show peak separations of 
greater than the 0 mV expected for surface adsorbed redox moieties, providing further 
evidence of sluggish adsorption-controlled electron transfer kinetics. 
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Figure 23: Cyclic voltammetric analysis 
 
Taking into account that the electroactive centres of the labels on the mononucleotide 
digest fragment and the oligonucleotide probe were both adsorbing to the electrode, it 
is clear that differences in diffusion will not account for the observed difference in 
peak oxidation current. 
 
If the response from a glassy carbon electrode and a SPCE is compared, it is clear that 
a clearer discrimination is observed from a SPCE (Figure 24). 
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Figure 24: Comparison of response on varying electrode surfaces 
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5.5: Scanning Electron Microscopy of Electrode Surface 
 
The SPCEs were studied using Scanning Electron Microscopy (Figure 25). 
 
Figure 25: SEM Image of SCPE surface 
 
Figure 25 clearly illustrates the porous open structure of the electrodes, made up of 
carbon graphite fragments held in a matrix with a PVC binder.  The porous nature 
inherent in the electrode manufacture process not only accounts for the order of 
magnitude higher currents being measured relative to a planar carbon electrode
125 
but 
may also offer explanation of the discrimination between a labeled mononucleotide 
and a labeled oligonucleotide.   
 
If the situation that all labeled and unlabelled oligonucleotides and digest fragments 
are adsorbing to the electrode is considered, in a successful T7 exonuclease digest 
assay, all fragments will be mononucleotide, or at least smaller fragments of 
oligonucleotide, depending on the efficacy of the enzyme in the assay conditions.  In 
this case, the labeled mononucleotide has easy access into the porous structure of the 
electrode matrix, resulting in efficient electron transfer, higher concentrations of 
electroactive label at the electrode surface matrix and thus higher observed oxidation 
currents.    
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In a mis-match assay where no exonuclease activity occurs, the molecular probe will 
be in tact and strands of oligonucleotide of tens of bases will adsorb onto the electrode 
surface.  If the steric bulk of DNA on the electrode surface in this case is considered 
along with the anionic repulsion of the DNA layer to oligonucleotide fragments, 
labeled or unlabelled, access of the electroactive centre of the probe i.e. the label, to 
the electrode matrix is hindered severely, resulting in poor electron transfer and lower 
resultant oxidation current. 
 
5.6: Eox – Consideration of Oxidation Potential 
 
Figure 26 illustrates the differential pulse voltammogram of probe CHLJAOL3 in 
both a positive and negative mungbean endonuclease assay (“Methods”).   
 
 
Figure 26: Difference in oxidation potential between digested and undigested fragments 
 
It is interesting to note the difference in potential of the oxidation peaks for the 
digested and undigested probe of c.25mV.  This result also supports the theory of an 
adsorption-controlled electron transfer mechanism through the porous matrix of the 
electrode.  If we consider the electron transfer from the digested fragment, i.e. 
labelled mononucleotide, the fragment has easy access to the pores of the electrode 
and hence less impeded electron transfer to the surface.  If we consider the undigested 
labeled probe however, the oligonucleotide portion of the probe may adsorb onto the 
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electrode and the electrochemical label, through steric consideration may be relatively 
far from the electrode itself, as illustrated in Figure 27.   
 
 
Figure 27 (below) indicates, schematically, the theory of discrimination mechanism. 
 
 
 
Figure 27: Schematic of electrode process 
 
 
The electroactive centre of the probe, being relatively far from the electrode surface is 
unlikely to yield an electron to the electrode directly, but the electron may „hop‟ via 
the DNA electrolytic chain to the electrode surface, resulting in a less efficient 
transfer mechanism and thus a higher oxidation potential is required in this case.  If 
we also consider the SPCE to have a matricised surface containing pores of various 
sizes, the effective surface area for electron transfer is also increased.  With the digest 
matrix containing enzyme, proteins and DNA, it is likely that a large degree of 
Easy access of digest  
Fc-mononucleotide into  
electrode matrix 
= high current 
Porous C electrode 
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adsorption will occur at the electrode.  The model described here renders the electrode 
accessible to small electroactive moieties through the porous structure and an 
enhanced electron transfer may occur.  Electron transfer through DNA has been 
thoroughly investigated and has such been widely exploited as a polyelectrolyte in 
sandwich assays
126
. 
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Chapter 6 - Synthetic Targets 
 
With a range of labels available for potential use in an electrochemical gene detection 
assay, it was decided that the following labels would be employed: 
 
Probe Name Label Employed Eox vs. Ag|AgCl Target Gene Detected 
CHL1 JAOL3 0.075V Cryptic plasmid of C. trachomatis 
NG2 JAOL4 0.2V Opacity gene of N. gonorrhoeae 
BA3 JAOL1 0.315V Human beta-actin 
 
As discussed in “Label Design and Synthesis”, the label used for probe NG2, consists 
of a di-ferrocenyl electroactive centre, exhibiting an oxidation peak height of, on 
experimental average, 6 times that of the monoferrocenyl electrochemical labels 
developed.  In order for the sensitivity of the other probes‟ oxidation current within 
the assay not to be compromised by the large current potentially exhibited by label 4, 
it was decided that the probe was to be used at a 1:10 dilution in H2O when used in 
conjunction with other electrochemical probes, as the observed peak currents pre- and 
post- enzymatic digest were within the same order of magnitude as those exhibited by 
CHL1 and BA3. 
 
In order to assess the potential applicability of each label to electrochemical gene 
detection, whether used singularly, or within a multiplex system, dose – response 
profiles were experimentally established and limits of detection (L.O.D.s) derived. 
 
Synthetic target gene sequences were purchased from Sigma Genosys and pre-diluted 
in H2O for use within the following nuclease digest matrix at varying concentrations. 
 
 
 
 
 
 
 
 74 
Material Volume (L) 
H2O 67 
0.1% Tween-20 (in H2O) (Purchased 
from Sigma-Aldrich) 
10 
GE 10xPCR Buffer  10 
Probe  3 
Synthetic Target 5 
T7 Exonuclease 5 
 
The assay was subsequently performed as per “Methods” and the resultant dose – 
response profiles are displayed (Figure 28). 
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Figure 28: Dose/Response analyses 
 
The sensitivity of the detection assay, experimentally determined here, is somewhat 
academic.  If the application of an assay such as this is considered, the amount of 
pathogenic DNA presenting a sample becomes unimportant.  Furthermore, the amount 
of pathogenic DNA present will be highly dependent on the sample collection 
technique and from where, anatomically, the sample is taken.  The crucial factor 
determined in this study is the L.O.D. as it is the absolute presence of the pathogenic 
DNA that needs to be detected in order for effective treatment to be administered. 
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L.O.D.s were calculated using the upper value of 3 standard deviations from the mean 
value for the peak oxidation current obtained when no synthetic DNA target is present 
in the assay.  This value is crucial in terms of assay development as this is deemed the 
threshold concentration of DNA that PCR must generate in order for the enzymatic 
electrochemical detection assay to be valid.  The values obtained are highly 
encouraging as these concentrations of DNA are easily obtained during a 40-cycle 
PCR, as employed in this assay (Methods). 
 
With the validity of each of the electrochemical probes established with the T7 
exonuclease detection assay, a triplex synthetic assay, comprising of all three 
molecular probes was performed as per “Methods”.  For a negative permutation of the 
assay, i.e. gene sequence absent, each of the probes‟ complementary target gene 
sequence was substituted for a synthetic recognition sequence from the CTR gene of 
N. meningitidis.  The results of this study are displayed below (Figure 29). 
 
Figure 29: Synthetic Target responses for positive and negative assays 
 
Visually, good discrimination between a gene sequence present (positive) and gene 
sequence absent (negative) is observed.  Statistical analysis supports assay validity 
from an analytical perspective, with data being valid for positive and negative 
samples within 3 standard deviations of the mean value obtained for each data set 
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(five replicate experiments) and a 99.7% confidence level for a true positive or 
negative result being established.  Thus, diagnostic cut-offs do not overlap and the 
probability of obtaining a false positive or a false negative result is 0.3%. 
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Chapter 7 - Assay Development using Genomic Targets, Leading to 
Clinical Screening of Anonymous Patient Samples 
 
7.1 – Initial Analysis of Triplex PCR for Genomic Targets of C. trachomatis 
(CT), N. gonorrhoeae (NG) and Human β-actin 
 
Thus far, the assay has been successfully applied to commercially synthesised target 
fragments for the human β-actin gene, an opacity gene in Neiserria gonorrhoeae and 
the cryptic plasmid in Chlamydia trachomatis.  In this chapter, we investigate the 
development of the assay in order to amplify and subsequently detect the above gene 
sequences using “real”, or biological, genomic targets in order to determine whether 
the assay is suitable for patient sample analyses. Refer to “Methods” for all primer, 
target and probe sequences referred to herein. 
 
The human β-actin gene was chosen as a target for an internal control for assay 
validation, owing to the pre-developed PCR conditions and probe-target recognition 
electrochemistry by Atlas Genetics (formally Molecular Sensing) and the fact that it 
will be present in any human clinical sample. Refer to “Methods” for details of the 
sequence and amplicon. 
 
Using the BACTIN3 PCR cycle (Methods), each genomic target was amplified 
individually in order to assess to effectiveness of the thermal cycling program for 
each genomic target. The successful conclusion of this test (BACTIN3 could amplify 
NG and CHL in addition to β-actin) led to the attempt to use this BACTIN3 to 
amplify two or more target gene sequences at the same time: a duplex or triplex PCR.  
 
An initial triplex PCR was subsequently performed using BACTIN3 cycling 
parameters, using the amplification mix, detailed in table 9.  Negative PCR controls 
were also run, using all PCR primers, but sigma water was used instead of DNA.  In 
each case, a 20µL reaction volume was used. 
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 Chlamydia Gonorrhoea β-actin Triplex 
Reagent Volume 
(µL) 
Volume (µL) Volume 
(µL) 
Volume 
(µL) 
10xPCR Buffer (GE – Chalfont St Giles, 
Buckingham, UK) 
2 2 2 2 
1.5mMdNTPs (Promega – Southampton, UK) 2 2 2 2 
10μM Primer FCHL (Sigma Genosys – 
Gillingham, Dorset, UK) 
1 1 1 1 
10μM Primer RCHL (Sigma Genosys) 1 1 1 1 
10μM Primer FNG (Sigma Genosys) 1 1 1 1 
10μM Primer RNG (Sigma Genosys) 1 1 1 1 
10μM Primer Fβ-A (Sigma Genosys) 1 1 1 1 
10μM Primer Rβ-A (Sigma Genosys) 1 1 1 1 
5000UmL
-1
Taq Polymerase (GE) 0.2 0.2 0.2 0.2 
25mM MgCl2 (GE) 1.2 1.2 1.2 1.2 
8.5x10
-7
 EBmL
-1
 DNACHL (US Biological – 
Swampscott, Massachusetts, USA) 
2 0 0 2 
10µgmL
-1
 DNA NG (ATCC – Manassas, VA, 
USA) 
0 2 0 2 
10nM DNAβ-Actin (Sigma Genosys) 0 0 2 2 
H2O (Sigma Aldrich – Gillingham, Dorset, 
UK) 
10.6 10.6 10.6 2.6 
Total 20 20 20 20 
Table 9: Reagent Volumes for Individual and Triplex PCR of Genomic Targets: Chlamydia 
trachomatis, Neisseria gonorrhoeae and Human β-actin. 
 
In order to assess whether PCR amplification had been successful, the PCR products 
were run on an agarose gel, 10µL of the PCR product was added to 2µL of 6x 
Loading dye (Promega) and the sample was run on a 100mL 3% agarose gel (0.5x 
TBE), containing 10µL of 10mg/mL ethidium bromide at 100V.  Figure 30 illustrates 
the gel image resultant from this amplification matrix. 
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Figure 30: Gel Image of Individual and Triplex PCR of Genomic Targets for Chlamydia trachomatis, 
Neisseria gonorrhoeae and Human β-actin – Lane 1: DNA Ladder, Lane 2: Chlamydia (156bp), Lane 
3: β-actin (120bp), Lane 4: Gonorrhoea (90bp), Lanes 5 & 6: Triplex PCR, Lanes 7: Negative Control 
& Lane 8: DNA Ladder. 
 
Lanes 2 to 4 exhibit clear bands of PCR product, relating to each genomic target 
amplified within the PCR matrix.  There is, however, residual primer dimerisation 
product in lanes 2, 4 and 7.  This is attributable to the primer pairage being designed 
for uniplex PCR with no re-optimisation for a triplex PCR.  The triplex PCR, bands, 
however, (Lanes 5 and 6), showed preferential amplification of β-actin, with no 
apparent amplification of the other PCR targets. This problem of non-amplification of 
the CHL and NG targets was subsequently investigated. 
 
7.2 – Development of Triplex PCR for Chlamydia trachomatis, Neisseria 
gonorrhoeae and Human β-actin 
 
Gel Imaging of PCR in PCR Optimisation Study 
There are many factors to consider when designing a successful multiplex PCR, 
including magnesium concentration, primer concentration and primer annealing 
temperature.  In order to assess the comparative annealing temperatures of the primers 
used in this triplex PCR, bioinformatic software from IIT Biotech (Germany) was 
used
120
.  Table 10 displays the annealing temperature of each primer used in the 
triplex PCR.  
 
 
 
1 2 3 4 5 6 7 8Lane
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Primer Sequence (5’-3’) Annealing 
Temperature Tm 
Chlamydia Forward 
Primer (CHLF) 
CCCAAGCAACATCTCGGTACA 61
o
C 
Chlamydia Reverse Primer 
(CHLR) 
TGAAGCTGTAGCCGCGCTCGGT 59.1
o
C 
Beta-actin Forward Primer 
(BAF) 
TTGAAGCTGTAGCCGCGCTCGGTAG 69.58
o
C 
Beta-actin Reverse Primer 
(BAR) 
TTCACCCACACTGTGCCCATCTACGAAG 68.0
o
C 
Gonorrhoea Forward 
Primer (NGF) 
GTTGAAACACCGCCCGG 62.0
o
C 
Gonorrhoea Reverse 
Primer (NGR) 
CGGTTTGACCGGTTAAAAAAAGAT 57.4
o
C 
Table 10: Annealing Temperatures of Primers Used in Triplex PCR. 
 
The annealing temperature in the thermal cycling program used (BACTIN3) was set 
at 60
o
C.  It was therefore important to ensure that in order for each PCR target to 
become successfully amplified, each set of annealing temperatures for each primer 
pair as well as each genomic target is as similar as possible.   
 
If we consider the NGR, the annealing temperature is below that of the one set for the 
thermal cycling program and as such, amplification of this gene sequence is hindered, 
as observed in gel image BX.  Note also the relatively high annealing temperatures of 
the primers for the β-actin gene sequence.  Higher annealing temperatures will 
encourage successful hybridisation of these primers relative to the other targets and 
thus competitive amplification occurs, in this case, in favour of the β-actin target 
amplification (Figure 30). 
 
In order to address this imbalance, the IIT Biotech bioinformatic software
127
 was 
employed to re-design the anomalous primers, in conjunction with the gene target 
sequences.  Table 11 illustrates the resultant changes. 
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Superseding 
Primer 
Superceded 
Primer 
Sequence (5’-3’) Annealing 
Temperature Tm 
BAF2 BAF GAAGCTGTAGCCGCGCTCG 64.0
o
C 
BAR2 BAR CACCCACACTGTGCCCATCTAC 64.5
o
C 
NGR2 NGR TCCTTATTCGGTTTGACCGGTTAAAA 60.0
o
C 
Table 11: Primer Modification with Resultant Tm. 
 
In order to further elucidate factors affecting the near simultaneous co-amplification 
of all genomic targets in the triplex PCR, duplex PCRs for N. gonorrhoeae with β-
actin and N. gonorrhoeae with C. trachomatis were performed in 30µL reaction 
volumes, using 300nM of NGF and NGR2 primers and 300nM of the other primers 
(i.e. all primers were used in equimolar amounts).  PCR product (10µL) was added to 
2µL of 6x loading dye (Promega) and the sample was run on a 100mL 3% agarose gel 
(0.5x TBE), containing 10µL of 10mg/mL ethidium bromide at 100V.  Figure 31 
illustrates the gel image resultant from this amplification matrix. It can be seen in 
figure 31 that both NG and BA and NG and CT could be amplified simultaneously 
using the optimised primers and the BACTIN3 thermal cycling program. 
 
 
Gonorrhoeae + Beta-Actin 
AD 030407 Two duplex tests with 
Gonorrhoeae 
Gonorrhoeae + Chlamydia 
 
 
 
Figure 31: Duplex PCR Gel Electrophoresis – Lane 1: DNA Ladder, Lanes 2-4: N.gonorrhoeae (84bp) 
with beta-actin (118bp), Lanes 5-7: Negative Control, Lane 8: DNA Ladder, Lanes 9-11: 
N.gonorrhoeae (84bp) with Chlamydia (156bp), Lanes 12-14 Negative controls 
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Electrochemical Determination of PCR products from PCR Optimisation Study 
To the remaining 20µL of the PCR product, 1µL of each probe [CHL3 (75mV), 
Ng14-151(1:10) (200mV) and BA1(315mV)] was added, followed by 2µL of T7 
exonuclease and the matrix incubated as per Inc-J program (37
o
C for 20 minutes, 
followed by cooling to 16
o
C).  Electrochemical measurement was then performed 
using the Autolab with electrochemical parameters as detailed in “Methods”.  
Resultant voltammograms and gel image are displayed in Figure 32. 
 
 
                            N. gonorrhoeae and beta-actin     N. gonorrhoeae and Chlamydia 
0.0 0.1 0.2 0.3 0.4 0.5
6.0x10
-8
8.0x10
-8
1.0x10
-7
1.2x10
-7
1.4x10
-7
C
ur
re
nt
 / 
A
E / V vs. Ag|AgCl
 PCR + NG + BA
 PCR - NG - NG
 
Figure 32: Gel Image and Voltammograms showing differences in duplex compatibility with respect to 
NG.  Both traces show the NG peak at 170mV – voltammogram measured in the presence of probes for 
Gonorrhoea and Beta-Actin. Blue trace is a voltammogram resulting from co-amplication of N. 
gonorrhoeae and beta-actin and the red trace results from co-amplication of N. gonorrhoeae and 
Chlamydia. 
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Figure 31 illustrates that the amplification of N. gonorrhoeae is amplified to a greater 
extent when mixed with β-actin than with Chlamydia, as indicated by the brightness 
of the band (84bp) as well as the enhanced peak for N. gonorrhoeae (170mV) 
following T7 enzymatic digestion (Figure 32). As a consequence, the concentration of 
the primer pairage for Chlamydia was reduced to 100 nM, and a triplex PCR was 
performed using the modified primers and the reduced concentration of Chlamydia 
primers, as detailed in table 12. 
 
 
 Triplex 
Reagent Volume (µL) 
10xPCR Buffer (GE – Chalfont St Giles, Buckingham, UK) 3 
1.5mMdNTPs (Promega – Southampton, UK) 3 
10μM Primer FCHL (Sigma Genosys – Gillingham, Dorset, UK) 0.3 
10μM Primer RCHL (Sigma Genosys) 0.3 
10μM Primer FNG (Sigma Genosys) 0.9 
10μM Primer RNG (Sigma Genosys) 0.9 
10μM Primer Fβ-A (Sigma Genosys) 0.9 
10μM Primer Rβ-A (Sigma Genosys) 0.9 
5000UmL
-1
Taq Polymerase (GE) 0.3 
25mM MgCl2 (GE) 1.8 
8.5x10
-7
 EBmL
-1
 DNACHL (US Biological – Swampscott, Massachusetts, USA) 2 
10µgmL
-1
 DNA NG (ATCC – Manassas, VA, USA) 2 
10nM DNAβ-Actin (Sigma Genosys) 2 
H2O (Sigma Aldrich – Gillingham, Dorset, UK) 11.7 
Total 30 
Table 12: Reagent Volumes for Triplex PCR of Genomic Targets: Chlamydia trachomatis, Neisseria 
gonorrhoeae and Human β-actin. 
 
The PCR amplification was performed on a PCR Block, using the BACTIN3 
program.  10µL of the PCR product was added to 2µL of 6x Loading dye (Promega) 
and the sample was run on a 100mL 3% agarose gel (0.5x TBE), containing 10µL of 
10mg/mL ethidium bromide at 100V. 
 
Figure 33 illustrates the gel image corresponding to this experiment.  As evidence of 
preferential amplification of beta-actin in this case remained, a further triplex PCR 
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was performed, as per Table 12, but reducing the β-actin primer pairage to 100nM. 
This is shown on the right hand side, lanes 8-10. As observed in the gel image, an 
even amplification of all three genomic targets resulted, with no evidence of 
competitive amplification.  
 
   
Figure 33: Gel Image of Triplex PCR of Genomic Targets for Chlamydia trachomatis(156bp), 
Neisseria gonorrhoeae(84bp)  and Human β-actin(118bp)  – Lanes 1-3: Triplex PCR, Lanes 4-6: 
Negative Control, Lane 7: DNA Ladder, Lanes 8-10: Triplex PCR, Lanes 11-13: Negative Control, 
Lane 14: DNA Ladder.   
 
 
7.3 – Evaluation of the Electrochemical Triplex Assay 
With an established successful methodology for amplifying the three target gene 
sequences together in a triplex PCR, electrochemical analyses of the samples, along 
with statistical analysis becomes a crucial stage in the assay development.  
Confidence levels for the genomic analyses become important when dealing with 
patient samples as reference ranges need to be established in any clinical diagnostic 
protocol.  In the “Synthetic Targets” chapter, the confidence level for an 
electrochemical result using synthetic gene targets was calculated to be 99.7%, based 
upon a Gaussian distribution. 
 
With the added complexity involved in a biological assay involving multiplex 
amplification, the assay required re-evaluation in terms of the confidence levels 
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associated with an electrochemical result.  To this end, ten triplex PCRs were 
performed – 5 positive and 5 negative, as described in the methodology outlined in 
section 4.2.  Negative controls were performed using Sigma water in lieu of genomic 
DNA and 10µL of the PCR product was added to 2µL of 6x Loading dye (Promega) 
and the sample was run on a 100mL 3% agarose gel (0.5x TBE), containing 10µL of 
10mg/mL ethidium bromide at 100V in order to confirm successful amplification of 
the positive samples and non-contamination of the negative samples.  
 
To the 20µL of the PCR product, 1µL of each probe [CHL3 (75mV), Ng14-151(1:10) 
(200mV) and BA1(315mV)] was added, followed by 2µL of T7 exonuclease and the 
matrix incubated as per Inc-J program (37
o
C for 20 minutes, followed by cooling to 
16
o
C for ever).  Electrochemical measurement was then performed using the autolab 
with electrochemical parameters as detailed in “Methods”. 
 
Figure 34 illustrates a voltammogram of a negative triplex PCR (red trace), 
overlaying a positive triplex PCR (blue trace) (34A), with the analogous gel image 
(34B) 
 
 
 
34A: Triplex Electrochemical Voltammogram – Blue 
Trace – Positive Triplex Assay, Red Trace – 
Negative Triplex Assay. 
34B: Triplex Gel Image – Lane 1: DNA 
Ladder, Lanes 2-4: Positive Triplex, Lanes 5-
6: Negative Control, Lane 7: DNA Ladder. 
 
 
Experimentally, confidence in a result using this particular genomic assay is limited to 
one standard deviation, as at two standard deviations from the mean, the diagnostic 
cut-offs overlap.  Thus, a 68% confidence level in the assay is defined, based on the 
Empirical rule of Gaussian distribution.  Note how this confidence level is much 
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lower than that calculated for the synthetic target assay (99.7%), owing to the greater 
complexity of the biological case. 
 
Further work would be well spent investigating factors that could improve the assay 
confidence levels when working with genomic targets. 
 
7.4 – Analysis of Clinical Samples from the Royal Free Hospital, London 
 
The final part of this work looked at whether the assay could be used to identify 
presence or absence of bacteria in clinical samples 
 
Clinical samples were obtained from Dr. Clare Ling, Dept. Virology at the Royal Free 
Hospital in London, UK.  The samples were anonymous discard samples, which had 
been tested using a culture assay for Neisseria gonorrhoeae and using the BD 
Probetec
TM
 protocol for Chlamydia trachomatis.  The BD ProbeTec Chlamydia 
trachomatis amplified DNA assay is based on the simultaneous amplification and 
detection of target DNA using amplification primers and a fluorescently labelled 
detector probe. The amplification reagents are dried in two separate disposable 
microwell strips. The processed sample is added to the Priming Microwell which 
contains the amplification primers, fluorescently labelled detector probe, and other 
reagents necessary for amplification. After incubation, the reaction mixture is 
transferred to the Amplification Microwell, which contains two enzymes (a DNA 
polymerase and a restriction endonuclease) necessary for Strand Displacement 
Amplification (SDA) a particular amplification technique used widely in commercial 
DNA amplification-based diagnostics.  The Amplification Microwells are sealed to 
prevent contamination and then incubated in a thermally controlled fluorescent reader 
which monitors each reaction for the generation of amplified products. The presence 
or absence of CT is determined by relating the BD ProbeTec MOTA (Method Other 
Than Acceleration) scores for the sample to pre-determined cutoff values. The MOTA 
score is a metric used to assess the magnitude of signal generated as a result of the 
reaction. 
 
The patient samples provided were 8 tested negatives for C. trachomatis and 6 tested 
positives for C. trachomatis.  All patients, however, were confirmed as negative for N. 
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gonorrhoeae.  Using the BD ProbeTec protocol, patient samples, whether they are 
urine or in a swab elution buffer, were initially centrifuged for thirty minutes at 2000 
g and the supernatant carefully decanted in order to minimize any inhibition of the 
amplification stage.  The samples were then lysed at 114
o
C.  Of each patient, two sub-
samples were provided, one lysed and one unlysed.  The lysed samples in each case, 
were used in the assay in order to improve amplification. 
 
Table 13 indicates patient numbers for the samples provided, including the result of 
their analysis at the Royal Free Hospital. It should be noted that the assay was 
performed „blind‟. It was not until later discussion with the RFH that the veracity of 
our assay was established. 
 
Samples Typed Negative for C. trachomatis 07M195165 
07M195167 
07M195175 
07M195172 
07M195180 
07M195179 
07M195178 
07M195176 
Samples Typed Positive for C. trachomatis 07M194999 
07M195129 
07M195831 
07M195139 
07M195123 
07M195149 
Table 13: Sample Identification 
  
 
7.4.1 – Detection of C. trachomatis in a clinical sample 
Initially, it was important to establish whether Chlamydia could be detected in a 
clinical sample.  To this end, samples 07M195123 (Positive) and 07M195167 
(Negative) were subjected to PCR amplification, using the BACTIN3 thermal cycling 
program and the reaction matrix displayed in Figure 35.  PCR negative controls were 
also performed using sigma water. 
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 Triplex 
Reagent Volume (µL) 
10xPCR Buffer (GE – Chalfont St Giles, Buckingham, UK) 3 
1.5mMdNTPs (Promega – Southampton, UK) 3 
10μM Primer FCHL (Sigma Genosys – Gillingham, Dorset, UK) 0.3 
10μM Primer RCHL (Sigma Genosys) 0.3 
5000UmL
-1
Taq Polymerase (GE) 0.3 
25mM MgCl2 (GE) 1.8 
BD Probec Sample  (Royal Free Hospital – London, UK) 2 
H2O (Sigma Aldrich – Gillingham, Dorset, UK) 19.3 
Total 30 
Figure 35: PCR Components for Clinical Sample PCR 
 
10µL of the PCR product was added to 2µL of 6x Loading dye (Promega) and the 
sample was run on a 100mL 3% agarose gel (0.5x TBE), containing 10µL of 
10mg/mL ethidium bromide at 100V. 
 
To the remaining 20µL of the PCR product, 1µL of each probe (CHL3, Ng14-
151(1:10) and BA1) was added, followed by 2µL of T7 exonuclease and the matrix 
incubated as per Inc-J program (37
o
C for 20 minutes, followed by cooling to 16
o
C ).  
Electrochemical measurement was then performed using the Autolab with established 
electrochemical parameters (Methodologies). 
 
Figure 36 displays a voltammogram of the PCR Negative (red trace), overlaying a 
negative amplified patient sample (07M195167 - blue trace) and the positive 
amplified sample (07M195123 - green trace) (36A), with the analogous gel image 
(36B). 
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36A: Chlamydia Voltammogram 36B: Chlamydia PCR Gel Image 
 
 
7.5 Chlamydia with beta-actin (Internal Control) gene 
 
To samples 07M195167 (patient negative for CT) and 07M195123 (patient positive 
for CT), and a duplex amplification of chlamydia with β-actin was performed, using 
the parameters as decribed in “Methods”.   β-actin was spiked into the PCR mixture 
(as detailed per “Methods”), at a concentration of 10nM prior to addition into the PCR 
reaction. 
 
Figure 37 displays a voltammogram of the PCR Negative (red trace), overlaying a 
negative amplified patient sample (07M195167 - blue trace) and the positive 
amplified sample (07M195123 - green trace) (inset into figure), with the analogous 
gel image. 
 
 
 
Figure 37: Gel Image and Voltammogram from Duplex PCR of Clinical Samples 
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7.6 Screening of clinical samples for CT and NG 
 
Each clinical sample was subsequently tested for the presence of chlamydia and 
gonorrhoea, using a triplex amplification as detailed in “Methods”.  The results of the 
study are illustrated in Figure 38. 
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Figure 38: Results from the Clinical Samples Screen for NG and CT with β-actin internal control gene. 
 
The amplification of each sample was confirmed by agarose gel electrophoresis and 
visualised by UV light.  As observed, successful amplification and detection of both 
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chlamydia and β-actin occurred in the chlamydia-postive samples, whilst only β-actin 
was detected in the chlamydia-negative samples. 
 
The absence of gonorrhoeal infection for the negative samples was subsequently 
confirmed by the Royal Free Hospital, hence indicating the veracity of the assay in 
this case. 
 
We have thus, from clinically-gained patient samples, successfully amplified 
chlamydial inclusions and an introduced internal control gene.  Furthermore, using the 
T7 exonuclease electrochemical digest assay, we have managed to discriminate, with 
confidence, patients validated as either positive for chlamydial infection or negative, 
as validated by commercially-used clinical diagnostics. 
 
Further investigation would be well spent using typed positive gonorrhoeal and 
chlamydial samples in order to strengthen the validity of the assay.  The use of human 
beta-actin inherent in the collected clinical samples, instead of artificial addition as an 
internal control for the assay would also be beneficial and further work could 
substantiate this. 
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